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Primary cilia are non-motile microtubule-based organelles that extend from the apical 
plasma membrane of most vertebrate cells and mediate signaling pathways. Mutations in ciliary 
genes often result in renal cyst formation, yet, the mechanisms connecting primary cilia 
dysfunction to renal cystogenesis are unclear. To address this gap, I have examined the role of 
ciliary-mediated Hedgehog (Hh) signaling in human and mouse models of the most common renal 
cystic disease, Autosomal Dominant Polycystic Kidney Disease (ADPKD), and have investigated 
initiating mechanisms of renal cystogenesis in a ciliary mouse model, Thm1 conditional knock-out 
(cko) mice. Here, I show that human ADPKD renal tissue has increased Hh activator, GLI1, in the 
nuclei of interstitial and cyst-lining epithelial cells, indicating increased paracrine and autocrine 
Hh activity, respectively. Further, Hh inhibitors reduced cell proliferation and microcyst formation 
of ADPKD primary cells, suggesting a functional role for increased Hh signaling in human 
ADPKD.  To extend these investigations to mouse models, I downregulated Hh signaling 
genetically in jck, Pkd1 and Pkd2 cko mice on mixed strain backgrounds and found a trend toward 
reduced kidney weight/body weight ratios in jck and Pkd1 cko mice, suggesting increased Hh 
signaling has a role in renal cystogenesis in vivo. Finally, to investigate initiating mechanisms of 
renal cystogenesis in Thm1 cko mice, RNA sequencing was performed on whole kidney extracts, 
which revealed approximately 10 genes that are upregulated in both pre-cystic and cystic kidneys.  
Collectively, these genes are typically expressed by renal epithelial cells, endothelial cells and 
immune cells, suggesting misregulation of genes and pathways in all three compartments may 
potentiate Thm1 cko renal cystogenesis.  Of these 10 molecules, STAT3 appears most prominently 
activated and present in epithelia of non-dilated, dilated and cystic tubules and in the interstitium.   
Interestingly, IL6 cytokine-treated THM1 knock-down 293T human renal cells showed a more 
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robust second wave of STAT3 activation that is preceded by enhanced ERK activation, suggesting 
that THM1 regulates STAT3 and ERK signaling.  Together, these data are the first to suggest 
increased Hh signaling has a role in ADPKD disease progression and increased STAT3 signaling 
has a role in disease initiation in a ciliary mouse model. Hh and STAT3 inhibitors are FDA-
approved, and therefore, these pharmaceutical therapies may potentially be repurposed to treat 
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1.1 Primary cilia structure and assembly   
Cilia are microtubule-based organelles that protrude from the apical plasma membrane of 
cells.  Cilia are conserved across species, from one-celled organisms, such as Chlamydomonas 
reinhardtii and Tetrahymena thermophile, to invertebrates, such as Drosophila melanogaster 
and Caenorhabditis elegans, and to vertebrates and mammals [1-3].  Cilia are classified as motile, 
which occur as tufts on a cell and confer motility, or non-motile, which are present singularly on 
a cell and have a sensory role.  In 1898, mammalian non-motile, primary cilia were first reported 
by Zimmermann, who proposed that these structures on renal epithelial cells sense fluid flow.  
These sensory organelles are essential for development and tissue homeostasis, and dysfunction 
of primary cilia results in disease, including Polycystic Kidney Disease (PKD) [4-6].  
Primary cilia consist of an axoneme, comprised of nine microtubule doublets, that is 
ensheathed by a ciliary membrane and extends from a basal body, which is a modified centriole 
[7]. From the basal body, transition fibers, which enable centriole docking to the plasma membrane 
prior to ciliogenesis, extend to the transition zone, which acts as a ciliary gate, regulating the 
molecules that enter and exit the cilium [8] (Figure 1.1).  
Primary cilia formation is coupled to the cell cycle, with cilia assembling when cells stop 
proliferating and disassembling when cells enter the cell cycle [9-11].   Prior to ciliogenesis, 
centrioles migrate to the apical plasma membrane and the mother centriole forms the basal body. 
Cilia are then synthesized and maintained by intraflagellar transport (IFT), which is the bi-
directional transport of proteins along the microtubular axoneme. Anterograde IFT transports 
molecules from the base to the tip of cilium and is mediated largely by IFT complex B proteins 
(IFT172, IFT88, IFT81, IFT80, IFT74, IFT57, IFT54, IFT52, IFT46, IFT27, and IFT20) and the 




mediated by IFT complex A proteins (IFT144, IFT140, IFT139, IFT122, IFTA-1, and IFT43) and 
the cytoplasmic dynein motor [5, 11, 12]. Bardet-Biedl Syndrome (BBS) proteins are also 
important for ciliary protein transport.  Eight BBS proteins form a complex called the BBSome, 
which interacts with Rab8, a nucleotide exchange factor, at the base of cilia, targeting vesicles to 
the cilium and promoting ciliary elongation [13].  Primary cilia act as mechanosensors and mediate 













Figure 1.1: Primary Cilia structure and IFT transport.  
The axoneme, transition zone and basal body are main components of the cilium. Anterograde and 
retrograde IFT are also represented in the image. Taken from Valente, E.M., et al., Primary cilia 
in neurodevelopmental disorders. Nature Reviews Neurology, 2013. 10: p. 27 [14]. Image reprinted 













1.2. Ciliopathies: Linking ciliary dysfunction to renal cystic disease 
 
Ciliopathies are disease syndromes caused by mutations in genes that encode proteins that are 
important for ciliary structure and function. Since primary cilia are present on most cells 
throughout the body, ciliopathies affect multiple organ systems and clinical manifestations include 
obesity, skeletal dysplasia, and very commonly, cystic kidney disease [6] (Figure 1.2). Obesity is 
a cardinal feature of two ciliopathies, Bardet-Biedl Syndrome (BBS) and Alström Syndrome 
(ALMS) [15, 16], while skeletal dysplasia is a feature of ciliopathies like Jeune Syndrome (JATD) 
and Ellis van Creveld (EvC) [6, 17]. In contrast, renal cysts are featured in most ciliopathies. 
Treatment for ciliopathies is limited and cures are lacking [18].  Notably, certain clinical 
manifestations of ciliopathies are also observed in the general population.  For instance, obesity 
affects 1 in 3 individuals in the United States [18], skeletal dysplasia affects 1 in 5,000 [19] and 
cystic kidney disease affects 1 in 500 worldwide [18].  Thus, studying ciliary genes and ciliary-
dependent mechanisms may also contribute to better understanding of the pathogenesis of common 















Figure 1.2 Clinical manifestation of ciliopathies.  
Ciliopathies affect multiple organ systems since primary cilia are present on most cells throughout 
the body. Renal cystic disease is among the most common clinical manifestations in ciliopathies 
and is the focus of my studies.  Taken from Goetz, S.C. and K.V. Anderson, The primary cilium: 
a signalling centre during vertebrate development. Nat Rev Genet, 2010. 11(5): p. 331-44 [5]. 







1.2.1 Renal Disease 
The kidneys are one of the most affected organs in ciliopathies.  Renal diseases caused by 
ciliary dysfunction range from infantile to adult disorders and are characterized by renal cysts and 
fibrosis to varying extents [6]. Depending on the genes mutated, cilia-related renal diseases are 
classified as either non-Polycystic Kidney Disease (non-PKD) or PKD.  BBS, Meckel-Gruber 
syndrome and nephronophthisis (NPHP) represent non-PKD diseases, while Autosomal Recessive 
PKD (ARPKD) and Autosomal Dominant PKD (ADPKD) comprise PKD.  BBS and Meckel-
Gruber Syndrome are characterized by renal dysplasia, resulting from defective differentiation of 
the renal parenchyma during kidney development and resulting in smaller kidneys that may have 
small cysts [6].  NPHP is caused by mutations in one or more of 20 genes (NPHP1-NPHP11, 
NPHP 1L, THM1 and SDCCAG8) and represents the most common chronic kidney disease 
affecting individuals within the first three decades of life and causes end-stage renal disease in 
approximately 5% of patients. NPHP patients manifest cortico-medullary cysts and may present 
extra-renal abnormalities, such as retinal disease and fibrocystic liver disease [6]. The NPHP gene 
products, the nephrocystins, localize to primary cilia, basal bodies and centrosomes and have been 
found to interact with other ciliary proteins, such as BBS proteins. Finally, PKD is classified as 
either ARPKD or ADPKD [6]. ARPKD is a rare disease that affects 1 in 20,000 births and is 
caused by mutations in PKHD1 (Polycystic Kidney and Hepatic Disease 1), which encodes the 
ciliary protein, fibrocystin.  ARPKD leads to cysts being formed in renal collecting ducts, but also 
causes extra-renal manifestations, such as hepatic and pancreatic cysts.  End-stage renal disease 
occurs in 30% of children with ARPKD.  In contrast, ADPKD is the most commonly inherited 
kidney disorder, affecting 1:500 people worldwide. ADPKD is caused by mutations in PKD1 or 




kidneys show cysts in all nephron segments, but most cysts are present in the collecting ducts.  
Cysts compress and damage surrounding renal tissue, which compromises renal function and can 
lead to end-stage renal disease by the 6th decade of life [20]. Since my thesis work focuses on 
ADPKD, I will elaborate more on this topic in Section 1.2.1.1. 
There are differences between non-PKD and PKD renal cystic diseases. Non-PKD diseases are 
characterized by abundant renal fibrosis, resulting in reduced kidney size, while PKD patients 
present with massive cyst growth that increases kidney size and damages neighboring parenchyma 
causing fibrosis [21]. Additionally, mutation of non-PKD genes compromises cilia structure, while 
mutation of PKD1 or PKD2 generally does not. In mice, mutation of Ift-B genes causes absent or 
shortened primary cilia [22-24] and mutation of Ift-A genes results in shortened cilia with 
accumulation of proteins at the ciliary distal tip [25, 26].  In contrast, cyst-lining epithelial cells in 
human and mouse ADPKD kidneys generally have structurally intact primary cilia [21, 27]. 
However, increased ciliary length was reported on Pkd1-/- and Pkd2-/- cultured mouse renal 
epithelial cells [28] and on renal epithelial cells of the Pkd1RC/RC mouse, which carries a PKD1 
hypomorphic mutation that was identified in human ADPKD patients [29].  Interestingly, next-
generation sequencing analysis of the genomes of 7 ADPKD patients revealed that each sample 
harbored truncating mutations in 5 to 15 ciliary genes, including genes associated with the basal 
body or centrosome, such as PCM1, ODF2, HTT, CEP89 and KIF19, and genes required for 
intraflagellar transport and the transition zone, such as IFT172, IFT80, NUP37 and NUP62 [30].  







1.2.1.1 ADPKD Diagnosis 
In ADPKD, renal fluid-filled cysts have been shown to develop in utero but grow very slowly 
and compromise renal function typically in adulthood [20] (Figure 1.2.1.1).  Other clinical 
manifestations include pain, urinary tract infections, renal stones, hematuria, liver cysts, 
hypertension and cardiovascular complications, which are responsible for the majority of deaths 
[31].  
The diagnosis of ADPKD is carried out by imaging studies in patients with a family history of 
the disease. Ultrasonography is the most common method, due to lower cost and availability, but 
more sensitive methods, such as computed tomography and magnetic resonance imaging, are also 
used.  Lastly, genetic testing is an option in cases where imaging and family history do not provide 
certainty on the diagnosis [31].   
Genetic tests include screening for mutations in PKD1 and PKD2, which account for ~85% 
and 15% of ADPKD cases, respectively [6]. Mutation of PKD1 results in more severe disease than 
mutation of PKD2, and is thought to be due to earlier onset of cysts [20].  Curiously, in a few 
reported cases, mutations in PKD1 or PKD2 were not found, causing speculation of the presence 
of a third ADPKD locus [32]. Further analysis of ADPKD families showed ~3% of genetically 
unresolved cases have mutations in GANAB, which encodes glucosidase II subunit a (GIIa). Loss 
of GIIa leads to defective maturation and subcellular localization of PC1 and PC2 [33]. These 












Figure 1.2.1.1 ADPKD in human. Kidneys of 45-year old man with ADPKD. Reproduced with 
permission from Brown, J. A., Images in clinical medicine. End-stage autosomal dominant 
















1.2.1.2 Polycystins are ciliary proteins 
Polycystin-1 (PC1) is a large membrane protein with 11 transmembrane domains, a short 
cytoplasmic tail and a large extracellular region (Figure 1.2.1.2). The C-tail interacts with 
polycystin-2 (PC2), G proteins and proteins tethered to the cytoskeleton, while the N-terminus 
associates with additional proteins and carbohydrates.  Since PC1 has several binding partners, 
PC1 is expected to have a wide range of functions, accounting for the diverse clinical 
manifestations that result from dysregulation of PC1 [35]. PC1 localizes to primary cilia, tight 
junctions, adherens junctions and other cellular compartments [35], but its localization to primary 
cilia has been reported to be critical for its function [36]. Further, PC1 is highly expressed in 
developing kidneys and is downregulated in adult kidneys [37].   
PC2 is comprised of 6 transmembrane domains and a cytoplasmic C-terminus and N-terminus 
[35] (Figure 1.2.1.2). PC2 has homology to transient receptor potential channel subunits (TRPC) 
and has a nonselective cation channel activity that is permeable to calcium. PC1 and PC2 form a 
complex. Structural analysis of the human PC1/PC2 complex revealed one PC1 molecule interacts 
with three PC2 molecules [38]. The same study suggests PC1 has a segment that resembles the 
structure of ion channels but PC1 structure is positively charged, indicating PC1 likely does not 
have channel activity, unlike PC2 [38]. PC1/PC2 complex is found within the primary cilia 
membrane. PC2 is also present in other cellular compartments, such as the endoplasmic reticulum 
and mitotic spindles [35] (Figure 1.2.1.2). In the kidneys, PC2 is expressed during and after 
development [37]. PC2 has several binding partners, allowing for diverse functionality, which 
includes microtubule stabilization and calcium channel activity [37].  The function of the ciliary 
polycystin complex remains controversial.  The polycystin complex has been reported as a flow-




increase intracellular Ca2+ in response to physiological fluid flow [39] (Figure 1.2.1.2). This 
finding was suggested to link ciliary dysfunction to ADPKD, since homeostatic intracellular 
calcium levels are reduced in renal cells of ADPKD patients [39]. However, another group reported 
that ciliary calcium levels did not affect intracellular calcium, suggesting that the ciliary and 
intracellular calcium pools are distinct [40].  Moreover, the cilium has several calcium channels, 
such as Tmc7, TRPV4, and PKD1, PKD2, PKD1-L1, PKD1-L2, PKD2-L1, PKD2-L2 and alpha-
epithelial sodium channel, but only si-RNA for PKD1-L1 or PKD2-L1 in human RPE cells reduced 
both inward and outward ciliary currents, suggesting PC2 may not be required to allow ciliary 




















Figure 1.2.1.2 Polycystin-1 and Polycystin-2 localize to primary cilia.  
PC1 and PC2 form a complex within the primary cilia membrane and have been proposed to 
mediate ciliary calcium signaling. Taken from Abdul-Majeed, S. and S.M. Nauli, Polycystic 
Diseases in Visceral Organs. Obstetrics and Gynecology International, 2011. 2011: p. 7 [43]. Open 
















1.2.1.3 Gene dosage or second-hit? 
ADPKD patients inherit the disease as an autosomal dominant trait, yet mice heterozygous 
for Pkd1 or Pkd2 do not develop cysts, and only manifest the disease when the mutation is in the 
homozygous form.  This has led to two hypotheses - gene dosage or second-hit - to explain how 
cyst formation is triggered and disease severity determined.  These hypotheses remain 
controversial, as evidence exists in support of either hypothesis (Figure 1.2.1.3).   
The gene dosage hypothesis proposes that the remaining functional PKD1 or PKD2 alleles 
in a patient are unable to sustain a threshold of PC1 and PC2 that is necessary to maintain renal 
tubular integrity, leading to cyst formation. This hypothesis is supported by studies that show that 
the type of mutation affects disease severity. For example, mice with an incompletely penetrant 
hypomorphic mutation (R3277C) in Pkd1, which has been identified in ADPKD patients, show 
different levels of disease severity when combined with different Pkd1 alleles. Pkd1RC/RC develop 
slowly-progressive disease, while Pkd1RC/- mice show rapidly-progressive renal cystogenesis [29]. 
Additionally, Pkd1+/-;Pkd2+/- mice also develop cysts, supporting the notion that a polycystin 
threshold is necessary to maintain tubular stability [44]. More recently, human PKD1 was shown 
to have abnormal patterns of splicing that truncate the PC1 protein, resulting in a novel smaller 
PC1 product and reduction of full-length PC1 [45]. These events do not occur in mouse, and the 
inherent decreased levels of full-length PC1 may cause humans to be more susceptible to cyst 
formation in the kidneys. Thus, these findings could account for why ADPKD develops in humans 
when a mutation is on 1 allele, but only develops in mice carrying mutations on both alleles. 
However, only 2-3% of nephrons are affected in ADPKD patients and cysts are monoclonal, 




supported by several findings. Renal epithelial cells have a high rate of somatic mutations, 
implicating secondary mutations in the loss of functional PC1 or PC2 [46].  
Further, the “developmental switch” phenomenon in mice, in which deletion of Pkd1, Pkd2 or 
other cystogenic gene before postnatal day (P)14, when kidneys are not yet fully developed, causes 
aggressive, rapidly-progressing renal cystic disease, while gene deletion after P14 results in very 
mild, slowly-progressive disease, suggests loss of PC1 is not the only important event in this 
disease [47]. Lastly, the observation that metanephric Pkd1-null kidneys develop cysts in vivo and 
yet cyst formation does not occur naturally when these kidneys are cultured ex vivo suggests 
elements in addition to Pkd1 loss are required for cystogenesis [48].  
A speculation that combines these two hypotheses suggests that reduction of polycystins below 
a threshold may initiate cyst formation, while a somatic mutation may aid in cyst expansion [44].  
Lastly, a third-hit hypothesis proposes that the environment contributes to severity of the disease 
by stimulating cellular processes such as inflammation and cell proliferation, which in turn 





















Figure 1.2.1.3 Cyst Formation in ADPKD.  
Schematic showing disease initiation involving a germ-line mutation and a somatic mutation or 
insufficient expression of PKD1 or PKD2.  Cysts form as a result of increased cell division.  
Swelling of the renal tubule pinches off from the tubule wall to form a cyst that continues to grow 
due to persistent fluid secretion.   Modified from Open Access Wallace, D.P., Cyclic AMP-
mediated cyst expansion. Biochim Biophys Acta, 2011. 1812(10): p. 1291-300 [49]. Image 


















1.2.1.4 cAMP/Ca2+ signaling in ADPKD renal cystogenesis 
ADPKD cells in cystic tubules have low levels of intracellular calcium (Ca2+) and increased 
levels and abnormal function of cAMP, an important ubiquitous second messenger, which are 
central to disease processes [49].   A few mechanisms that lead to increased cAMP levels have 
been proposed.  One is that decreased intracellular Ca2+ results in dysregulation of calcium-
regulated adenylate cyclases (ACs) and phosphodiesterases (PDEs), which in turn, leads to 
increased production of cAMP [49]. Another proposed mechanism involves arginine vasopressin 
(AVP), a hormone active in the collecting ducts and distal nephron. AVP binds vasopressin V2 
receptors, stimulates cAMP production, which activates protein kinase A (PKA), inducing higher 
water absorption back into circulation through aquaporin water channels [49]. In ADPKD cells, 
cAMP activates the mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 
(MAPK/ERK1/2) pathway, increasing cell proliferation, and activates the cystic fibrosis 
transmembrane conductance regulator (CFTR) to induce fluid secretion, enabling cyst growth [48, 
50].  Importantly, reducing Ca2+ levels in normal renal cells resulted in a PKD phenotype [51] and 
restoring intracellular Ca2+levels prevented the aberrant proliferative response to cAMP in cultured 
ADPKD primary renal cells [52].  These studies further support the critical role for calcium 
homeostasis in maintaining renal tubular integrity. 
 
1.2.1.5 Dysregulated ciliary length may contribute to renal cystogenesis in ADPKD  
In addition to the polycystin complex localizing to primary cilia, cAMP and PKA are also 
found at relatively high basal levels within the cilium, where adenylate cyclases and cAMP are 
thought to regulate ciliary length and PKA is thought to regulate GLI processing and Hedgehog 




cystogenesis in disease models. Primary cilia of jck and Pkd1RC/RC mutant mice are lengthened [29, 
55, 56], and pharmacological shortening and genetic ablation of cilia in jck mutant and Pkd1/2 cko 
mice, respectively, attenuated the renal cystic disease [57, 58]. In vitro studies with mammalian 
epithelial cells showed that decreased intracellular Ca2+and increased cAMP levels, followed by 
PKA activation, increase ciliary length [59].  Interestingly, ciliary length of renal tubule cells is 
modulated during renal injury and repair [60, 61], and Pkd1 and Pkd2 heterozygous mice are 
sensitive to acute ischaemia-reperfusion renal injury [62, 63]. The connection between ciliary 
length and disease models is not well understood, but ciliary length seems to be a dynamic process 
that needs to be closely regulated to sustain renal tubular integrity.  
 
1.3. Murine models of renal cystic disease 
Mouse models are valuable to elucidate the molecular mechanisms that lead to renal 
cystogenesis and to uncover new therapeutic targets against ADPKD. There is no model that 
recapitulates human ADPKD completely but the combination of studies using several models has 
helped advance research in this field. Here, I will describe the murine models that are relevant to 
my work. 
 
1.3.1 Pkd1 and Pkd2 orthologous mouse models of human ADPKD 
 Several mutant alleles of Pkd1 and Pkd2 have been generated in mice in attempt to mimic 
the human disease. Since homozygous deletion of Pkd1 and Pkd2 is embryonically lethal, 
conditional, hypomorphic and overexpression alleles have also been generated [64]. Conditional 
alleles are advantageous in that deletion can be cell- or tissue-specific and/or temporally regulated 




from P1 bacteriophage and recombines two directly or inversely oriented 34 bp loxP sites on 
double-stranded DNA [65]. Commonly used promoter-Cre recombinases to study PKD are the 
Ksp (Cdh16)-Cre, which is expressed in the distal tubule, loop of Henle and collecting duct, and 
the Rosa26-CreERT, which is expressed ubiquitously upon induction by tamoxifen.  This type of 
inducible Cre recombinase was instrumental in identifying the “developmental switch” 
phenomenon, in which Pkd1/2 deletion before kidneys have fully matured at P14 leads to rapidly 
progressing, severe renal cystic disease, while Pkd1/2 deletion after P14 results in slowly 
progressing, mild disease [47].  Since ADPKD progresses slowly, mouse models that take longer 
to reach end-stage renal disease may resemble the human disease more closely.  However, 
molecular mechanisms and pathways leading to renal cystogenesis in rapidly progressing models 
can be studied in a much more timely manner (3 weeks vs. 1 year) and have shown to also play a 
role in the human disease, indicating that both slow and fast progressing models have utility.   
 
1.3.2 Nek8 jck/jck mouse model 
In mice, a nucleotide substitution of valine for glycine at amino acid 488 in the C-terminal 
domain of NEK8 results in cystic kidney disease in a mouse model called juvenile cystic kidney 
disease (jck)[66] (Figure 1.3.2). NEK8 is a serine/theorine kinase and is 1 of 11 mammalian Never 
in Mitosis Gene A-related kinases (NEK) [67] (Figure 1.3.2).  jck mice have been reported to 
develop renal cysts by postnatal day 3 [66] and share several similarities with human ADPKD.  jck 
mice have a relatively slowly-progressing disease, developing ESRD around 4 months of age, and 
cysts develop from several segments of the nephron, including the distal tubule, collecting duct 
and loop of Henle [56].  Additionally, cAMP levels in the kidney correlate with disease 




factors lead to activation of B-Raf and ERK which contributes to cell proliferation, as seen in 
human ADPKD [52, 56]. Further, jck males have more aggressive cystic kidney disease than 
mutant females [56], a gender dimorphism that is also observed in human ADPKD [68]. Because 
of these similarities, jck mice have been considered a useful model to investigate human ADPKD. 
NEK8 localizes to centrosomes during interphase of dividing cells and to the proximal region 
of cilia in ciliated cells [69, 70].  In contrast, the jck mutation causes NEK8 to mislocalize along 
the entire length of primary cilia [71] and to increase ciliary length [56]. NEK8 is activated upon 
exit of the cell cycle when primary cilia are formed, but Nek8 knock-down does not affect 
ciliogenesis [69].  NEK8 also regulates G2/M proteins, indicating a role for NEK8 in the cell cycle 
[72]. Lastly, a GFP-NEK8 construct was localized to the nucleus [69, 73], where it was shown to 
be important for the ATM and Rad3-related (ATR) -mediated replication stress response.  Cells 
without functional NEK8 show increased double strand breaks which accumulate due to reduced 






Figure 1.3.2 Nek8 gene mutation in jck mice.  
A) Protein domain structure of the murine NEK8 protein. B) A Gly-to-Val substitution at amino 
acid 448 occurs in jck mutant mice. C) Region containing the jck mutation is conserved across 
species.  Regulator of chromatin condensation (RCC). Image republished with permission from 
The Company of Biologists Ltd, from A defect in a novel Nek-family kinase causes cystic kidney 
disease in the mouse and in zebrafish [67]. Development and Disease, Copyright 2002; permission 












1.3.2.1 Renal disease associated with NEK8 
Nephronophthisis (NPHP) is an autosomal recessive kidney disease that is caused by 
germline mutations in the human NEK family of genes.  NPHP causes renal cysts and fibrosis, 
progressing to end-stage renal disease (ESRD) in the first 3 decades of life [75]. NPHP accounts 
for 2.4% to 15% of ESRD in children [76]. NEK8 has also been implicated in cancer. A missense 
mutation in NEK8 was identified in a patient with pancreatic cancer [77], and NEK8 was shown to 
be overexpressed in human breast tumors [72].   
 
1.3.2.2 Relationship between NEK8 and Polycystins 
Two studies have investigated the relationship between NEK8 and the polycystins.  In one 
study,  NEK8 was demonstrated to interact with PC2 but not with PC1 [71]. Additionally, the jck 
mutation was shown to lead to misregulated phosphorylation of PC2, increased ciliary localization 
of the polycystins  and increased PC1 and PC2 levels in whole kidney extracts [71]. In the second 
study, single mutant embryonic kidney cultures of Pkd1-/- or Nek8jck/jck mice demonstrated that the 
level of the mutated gene plays a role in severity of cystogenesis, with more mutated alleles 
increasing cystogenesis [78]. Cysts formed in Pkd1-null or Nek8jck/jck single mutant embryonic 
kidney explants displayed dysfunctional cell-cell junctions, altered desmosomal protein expression 
and reduced E-cadherin levels, like ADPKD epithelia. Nek8 mutant cells show increased PC1 
within the cilium while Pkd1 mutant cells show increased NEK8 within the primary cilia, 
indicating an association between the proteins [78]. Importantly, Pkd1+/-; Nek8jck/+ double 
heterozygous mice developed renal cysts in adulthood, unlike single heterozygous animals, 





1.3.3 Thm1 mouse model 
 
In an ethylnitrosourea (ENU)-derived mouse mutagenesis screen for late developmental 
phenotypes, the alien (aln) mutant which exhibits polydactyly, craniofacial and neural tube defects 
was identified [79].  The aln phenotype is caused by a glutamine to proline change at residue 15 
in THM1 (Tetratricopeptide repeat-containing Hedgehog Modulator 1; also known as TTC21B), 
which causes the absence of THM1 protein [80]. aln mice die shortly after birth, and thus, a 
conditional allele of Thm1 is necessary to investigate THM1 function post-natally [80] (Figure 
1.3.3). Global deletion of Thm1 at E17.5 or P0 causes renal cystic disease by 6 weeks of age, with 
cysts deriving from proximal tubules, Loop of Henle and collecting ducts [80] (Figure 1.3.3.1).  
Consistent with other ADPKD mouse models, Thm1 conditional knockout (cko) mice show 
increased kidney to body weight ratio (KW/BW), increased cAMP levels, and increased blood 
urea nitrogen (BUN) levels, indicative of compromised renal function [80].  In contrast, global 
deletion of Thm1 at 5 weeks of age causes mild cystic kidney disease, consistent with the 
developmental switch, and the more prominent phenotype in these mice is obesity, due to 
hyperphagia or over-eating, indicating a role for THM1 in regulating appetite  [81].  
THM1 is orthologous to Chlamydomonas IFT-A component, IFT139. THM1 localizes 
throughout the ciliary axoneme in a punctate manner and THM1 deficiency causes shortened cilia 
with accumulation of proteins at the distal ciliary tip, reflecting the role of THM1 in mediating 
retrograde IFT [25].  
Epistasis analyses between aln, and Hh components, Smo and Gli2, revealed that THM1 
acts as a negative regulator of Hh signaling downstream of the SMO signal transducer but upstream 
of GLI2 transcription factor [25].  In cystic kidneys of Thm1 cko mice, increased Hh activity is 




with either control DMSO, or with Hh inhibitors, Gant61 or Sant2, showed that the Hh inhibitors 
reduced aln renal cystogenic potential [80]. Further, genetic downregulation of Hh signaling by 
Gli2 deletion in Thm1,Gli2 double conditional knock-out mice reduced renal cystogenesis, 
suggesting increased Hh signaling has a role in Thm1-mutant renal cystogenesis [80].  
 
1.3.3.1 Disease associated with THM1  
Mutations in THM1 were identified in ~5% of ciliopathy patients, rendering THM1 the 
most commonly mutated IFT gene. Mutations in THM1 cause disease, such as NPHP, also act to 
modify diseases, such as Bardet Biedl Syndrome (BBS), in which patients have been identified to 
harbor mutations on both alleles of a BBS gene in addition to a heterozygous pathogenic mutation 
in THM1 [82].  Additionally, THM1 mutations have been found in patients with Joubert Syndrome, 
a disorder of the cerebellum [83]. Cerebellar architecture requires Hh signaling, and interestingly, 
Thm1-deficient Bergmann glia cells showed decreased levels of GLI1, a Hh target that reflect Hh 
activity, suggesting that Thm1 acts as a positive regulator, rather than a negative regulator, of the 
pathway in these cells [83].   These studies demonstrate that regulation of Hh signaling by THM1 
and/or ciliary proteins is context-dependent. 
Lastly, a missense mutation in THM1 was the first ciliary mutation identified in patients 
with familial focal segmental glomerulosclerosis (FSGS).  FSGS affects podocytes and mature 
podocytes lack cilia [84]. This study showed that knock down of Thm1 in podocytes leads to 
cytoskeletal alterations and abnormal cell migration and suggested that THM1 plays an extra-








Figure 1.3.3: Protein structure of THM1 
THM1 protein is comprised of 1,317 amino acids and predicted by Pfam (http://pfam.wustl.edu/) 
to have 11 TPR motifs. Modified from paper: Tran, P.V., et al., THM1 negatively modulates mouse 
sonic hedgehog signal transduction and affects retrograde intraflagellar transport in cilia. Nat 
Genet, 2008. 40(4): p. 403-410 [25]. Reprinted with permission from Nature Genetics, copyright 





























Figure 1.3.3.1: Deletion of Thm1 results in ciliary phenotype and renal cystic disease in mice 
A) Scanning electron micrographs of primary cilia in collecting ducts.  Thm1 cko mice have 
shortened primary cilia with a bulb-like distal tip. B) Thm1 cko mice at P42 (6 weeks of age) have 
renal cystic disease.  Thm1 was deleted at E17.5. Image from Tran, P.V., et al., Downregulating 
hedgehog signaling reduces renal cystogenic potential of mouse models. J Am Soc Nephrol, 2014. 
25(10): p. 2201-12 [80]. Reprinted with permission from Journal American Society of Nephrology, 














1.4. Ciliary-mediated signaling pathways  
1.4.1 Primary cilia as mechanosensors of flow-induced calcium signaling 
Supporting Zimmerman’s proposition from the 1800’s that primary cilia of renal epithelial 
cells act as mechanosensors, flow-induced bending of primary cilia of renal epithelial cells 
increased intracellular calcium by increasing Ca2+ entry through Ca2+ channels and by releasing 
Ca2+ from intracellular Ca2+ stores [85].  Depletion of PC1 or PC2 abolished flow-induced increase 
in intracellular Ca2+, leading to the proposition that the ciliary-localized polycystin complex 
mediates flow-induced Ca2+ signaling [39, 86].   More advanced imaging technology further 
demonstrated that bending of cilia on renal epithelial cells increased ciliary Ca2+ and, subsequently, 
increased cytosolic Ca2+ [86, 87]. However, these findings and theories have become controversial 
because of reports from another group, who demonstrated that bending of primary cilia did not 
increase ciliary Ca2+, and moreover, increased ciliary calcium minimally affected intracellular Ca2+ 
levels in their system. Conversely, increases in intracellular Ca2+ elevated ciliary Ca2+ pools.   
Ciliary Ca2+ concentrations were also shown to be approximately 5-fold higher than intracellular 
Ca2+ concentrations, suggesting that these two calcium pools are independent of each other [40, 
88]. In addition to PC2, other TRP channels that can mediate calcium signaling localize to primary 
cilia [89, 90].  Studies from the same group that negated flow-induced ciliary Ca2+ signaling 
showed that TRP channels encoded by Pkd1L1 and Pkd2L1 generate ciliary calcium currents, 
while the polycystins did not [41].  These conflicting results could be due to the use of different 
cell models and imaging techniques. These contradictory data suggest that the function of primary 
cilia and the polycystin complex as mechanosensors to induce ciliary calcium signaling requires 





1.4.2 Hedgehog Signaling 
The mammalian Hedgehog (Hh) pathway is fundamental for development and tissue 
homeostasis and is the best characterized, cilia-mediated pathway [91].  Hh signaling was first 
identified in Drosophila melanogaster, which revealed core signaling components conserved 
across species. Hh ligand is modified and released to activate the Patched (PTCH) receptor, a large 
multipass transmembrane transporter-like protein, and consequentially, the Smoothened (SMO) 
signal transducer, ultimately causing post-translational modification and activation of 
Cubitus/Glioma (Cu/GLI) transcription factors [92]. 
 In mammals, many of the Hh signaling events occur at the primary cilium [93].  The pathway 
is initiated by one of three Hh ligands, Indian (Ihh), Dessert (Dhh) or Sonic Hedgehog (Shh). Hh 
ligands are lipid-based proteins that undergo post-translational modifications to be secreted by 
producing cells and transported [94, 95].  Hh ligands have tissue-specific roles. Ihh plays a role in 
bone development, Dhh in spermatogenesis and Shh is essential for neuronal cell fate in embryonic 
development [96]. During mouse development, Shh is first produced by cells in the notochord and 
the floor plate, but as development progresses, other cell types produce and release Hh ligands  
[96]. Upon ligand binding to the PTCH receptor present in the ciliary membrane, PTCH exits the 
cilium, and concomitantly, Smoothened (SMO), which is a member of the G protein-coupled 
receptors (GPCR), translocates to the primary cilium and is activated.  In canonical Hh signaling, 
SMO activates GLI transcription factors (GLI1, GLI2 or GLI3), which then translocate from the 
cilium to the nucleus to modulate transcription of Hh target genes, thus controlling cell 
proliferation, differentiation and cell fate (Figure 1.4.2). While GLI1 is an obligate transcriptional 
activator that functions in its full-length form, GLI2 and GLI3 can function as activators in their 




thought to function mainly as an activator, and GLI3 as a repressor [93, 97-99]. A series of 
phosphorylation and ubiquitylation events beginning with phosphorylation by protein kinase A 
(PKA) dictate the cleavage and activity of GLI proteins [91]. The ratio between the active and 
repressive forms of GLI transcription factors regulate canonical Hh signaling output in a tissue-
dependent matter [100]. Interestingly, Hh signaling can be activated independently of GLI 
transcription factors in a noncanonical pathway.  The activation and role of non-canonical Hh 
signaling are less well-defined than canonical Hh signaling [101].  
In mice, mutations in Ift genes result in embryonic phenotypes associated with dysregulated 
Hh signaling, demonstrating a central role of primary cilia in regulating the Hh pathway.  
Mutations in most Ift-B genes, which are required for anterograde IFT, result in absent or shortened 
primary cilia, and cause a loss of Hh signaling. This was shown in Ift172[22], Ift88[22], Ift52[23], 
and Ift57[24] mutant mice, which exhibit a loss of caudal neural tube ventral markers [93], which 
require Hh signaling [25]. In contrast, mutations in Ift-A genes, such as Thm1[25] and Ift122[26], 
which are important for retrograde IFT, cause shortened cilia with accumulation of proteins in a 
swollen, bulb-like distal tip.  These mutants also show upregulation of Hh signaling, with 
expansion of ventral-specific markers in the caudal neural tube [93]. Collectively, these data 
suggest opposing roles for Ift-A and Ift-B genes in regulating Hh signaling, or that Ift-A and Ift-B 
together finely tune regulation of signaling pathways.  
The mechanisms by which IFT complexes and individual IFT proteins modulate Hh 
signaling remain incompletely understood, but individual IFT proteins are also likely to have 
distinct roles. aln mutant embryos which lack THM1, show increased Hh signaling, and presence 
of GLI full-length proteins and SMO in mutant cilia [25]. However, mouse embryonic fibroblasts 




when cells were treated with a small molecule Hh activator and SMO agonist, SAG, suggesting 
different IFT complex A proteins have distinct roles in regulating transport of Hh signaling 

















Figure 1.4.2: Mammalian Hedgehog Signaling.  
Diagram on the left: Hh pathway in the absence of Hedgehog stimulus.  PTCH receptor is present 
in the ciliary membrane, preventing GLI transcription factors from being activated. Diagram on 
the right: Hh pathway in the presence of Hh ligand. Hh-bound PTCH exits the cilium, and SMO 
enriches in the cilium, where it is activated leading to activation of the GLI transcription factors. 
Image from Christensen ST, Ott CM., A ciliary signaling switch. Cell signaling, 2007. 20; 317:330 












1.4.2.1 Hh signaling in the kidney 
Shh and Ihh ligands are expressed in renal tubular epithelial cells [104]. Hh signaling is 
active in embryonic kidneys and dampened after development. In mice, Shh deficiency or 
pharmacological inhibition of SMO compromised renal organogenesis by decreasing levels of 
GLI1, GLI2 and GLI3A:Gli3R, and in turn, expression of kidney patterning genes and cell cycle 
regulators [105]. Importantly, elimination of Gli3 in Shh-/- mice allowed kidneys to develop 
normally and restored expression of affected genes [105]. These results are thought to be due to 
the role of GLI3 in regulating nephron formation [106].  
Hh signaling is a developmental pathway that is usually activated during organogenesis 
and downregulated following organ development. In contrast, inappropriate activation of the Hh 
pathway in adulthood is commonly associated with disease. Adult mice that underwent unilateral 
ureteral obstruction (UUO) developed renal fibrosis, which was associated with increased Gli1, 
Gli2 and Gli3 mRNA expression, suggesting increased Hh activity [104]. Interestingly, SHH and 
IHH ligands were present in renal epithelial cells, while GLI1 and GLI2 were found in the 
interstitium, suggesting paracrine Hh signaling in this model [104]. Enhanced Hh activity has also 
been suggested to play a role in renal cystic disease.  Increased Gli1 transcripts have been shown 
in cystic kidneys of several mouse models, including Arl13b, Ift140, Glis2, Thm1, jck and Pkd1  
[80, 107-109]  and genetic downregulation of the Hh pathway reduced renal cystogenesis in Thm1 
conditional knock-out mice [80].  Additionally, Hh inhibitors reduced renal cystogenic potential 
of jck and Pkd1 mutant embryonic kidneys cultured with cAMP [80]. Moreover, transcriptome 






1.4.2.2 Hh signaling in other diseases 
Increased Hh signaling is also associated with several cancers, such as basal cell carcinoma, 
medulloblastoma, lung, and renal cell carcinoma [111, 112]. Tumor cells release Hh ligand, which 
activates the pathway in the surrounding areas, promoting tumorigenesis. The pathway also 
promotes proliferation of cancer stem cells and is associated with promoting tumor invasiveness 
[111]. Interestingly, in vitro inhibition of Hh signaling reduced cell proliferation of renal 
carcinoma cells [112]. Several synthetic Hh antagonists are being tested in clinical trial for cancer 
[111].  
 
1.4.2.3 Hh modulators  
High-throughput screening for Hh modulators using various cell types has identified small 
molecule regulators of the pathway. SAG, a SMO agonist, activates the pathway by binding to 
SMO [113]. Cyclopamine, a Hh antagonist that interacts with SMO, prevents its activation, yet 
still allows SMO translocation to the primary cilium, illustrating that SMO ciliary translocation 
and activation are separate events [113-115]. In contrast, another SMO antagonist, Sant2, prevents 
Shh-induced SMO translocation to the cilium [113]. Itraconazole has been used as an anti-fungal 
therapy since 1988 and was discovered to antagonize SMO in the 2000s [116]. Itraconazole 
inhibits Hh by binding to SMO, on a different site than cyclopamine [116]. GDC-0449 is a SMO 
antagonist that is approved by the Food and Drug Administration (FDA) and is indicated to treat 
basal cell carcinoma, while ongoing studies aim to expand its recommendation for other diseases 
[117, 118]. Finally, Hh antagonists that inhibit targets downstream of SMO have also been 
identified. Gant61 is a hexahydropyrimidine that inhibits Hh signaling by interfering with the DNA 




1.4.3 Other ciliary-mediated pathways  
Since most vertebrate cells have primary cilia but not all cells have active Hh signaling, 
the possibility that primary cilia can mediate other signaling pathways was raised [5]. Indeed, Wnt 
and LKB1/AMPK signaling are pathways whose components have been localized to the cilium [5, 
90].  
Wnt signaling is conserved among species and plays a role in cell migration and 
development. Both canonical (β-catenin-dependent) and non-canonical (β-catenin-independent) 
Wnt signaling pathways are activated when ligand binds to frizzled receptors. In the canonical Wnt 
pathway, binding of the ligand to receptor increases levels of the transcription factor β-catenin. 
Inversin (INVS) is located at the base of the cilium and is increased in whole inner medullary 
collecting duct (IMCD) cell extract when flow is applied, in vitro.  INVS inhibits canonical Wnt 
pathway but is required for non-canonical Wnt signaling, acting as a switch between canonical and 
non-canonical Wnt signaling, [90, 120]. Kidney specific inactivation of Kif3a, a ciliary protein, in 
mice results in cystic kidney disease and increased Wnt signaling activity, suggesting a link 
between cilia and Wnt signaling [121]. However, mutations in Ift ciliary genes in mice do not 
cause phenotypes that resemble Wnt signaling dysregulation [5], suggesting that primary cilia may 
be more important for Hh signaling than Wnt signaling during mouse embryogenesis [122].   
Upon fluid flow, ciliary-localized liver kinase B1 (LKB1), a tumor suppressor kinase, 
phosphorylates AMP-activated protein kinase (AMPK), a molecule that senses energy levels. 
Upon phosphorylation, AMPK accumulates at the base of primary cilia, and downregulates the 
mammalian target of rapamycin (mTOR) pathway [123]. mTOR pathway plays a role in cell 
metabolism and growth and is upregulated in epithelial cells that line the cyst walls of human 




activator, attenuated renal cystic disease in PKD animal models [124-127]. However, clinical trials 
with mTOR inhibitors were unsuccessful in delaying disease progression [128-130].   
 
1.5. Loss of primary cilia partially rescued cystic kidney disease in a mouse model 
Paradoxically, loss of primary cilia in Pkd1 and Pkd2 conditional knock-out mice 
attenuates renal cystogenesis, which led to the proposal that a ciliary-dependent cyst-promoting 
mechanism occurs when polycystins are deficient [58].  Recently, ciliary PC1 was found to interact 
with a ciliary complex comprised of LKB1-ANKS3-NEK7-NPHP1, which suppresses expression 
of Ccl2, which encodes MCP1 (monocyte chemoattractant protein) and consequently regulates 
inflammation [131]. Pkd1,Ccl2 mutant mice showed reduced renal cystogenesis, suggesting that 
the immune reaction triggered by CCL2 may link primary cilia to renal cystic disease [131]. Thus, 
these studies suggest Ccl2 promotes PKD via a primary cilia mechanism and presents as a likely 
effective therapeutic target for ADPKD.   
 
1.6. Drug therapy for ADPKD 
The economic burden of ADPKD is estimated at several billions of dollars/year worldwide 
[132].  Drug therapy represents a good strategy to improve quality of life and reduce costs within 
the healthcare system. However, the molecular mechanisms underlying disease initiation and 
progression are not well understood, which makes development of drugs that effectively slow 
disease progression challenging. Several pharmaceutical approaches have been tested in clinical 
trials, including somatostatin analogs, mTOR pathway inhibitors, anti-hypertensives and 
regulators of the renin-angiotensin system, but most have not shown significant disease attenuation 




shown to significantly delay disease progression and is the only Food and Drug Administration 
(FDA)-approved drug for ADPKD. Tolvaptan decreases cAMP levels, which in turn decreases 
fluid secretion and cell proliferation [136].  The clinical success of Tolvaptan has led to clinical 
trials that focus on high water intake to mimic the effect of Tolvaptan [137]. Investigating and 
discovering cilia-mediated mechanisms leading to renal cystogenesis may provide novel drug 
targets and enhance therapy for PKD. 
 
1.7. Study Significance  
In this dissertation, in vitro and in vivo studies investigate cilia-mediated pathways that 
may play a role in initiation and progression of renal cystogenesis. In Chapter 2, I examine 
Hedgehog (Hh) signaling, an established cilia-dependent pathway, in ADPKD human primary 
cells and tissues. I have found that Hh inhibitors reduced in vitro proliferation and microcyst 
formation of ADPKD cells and that Hh activity is enhanced in cystic areas of ADPKD tissues, 
compared to normal human kidney tissues. These data suggest a role for Hh signaling in human 
ADPKD. While enhanced Hh activity plays an important role in various cancers and in renal 
fibroses, the pathway remains largely unexplored in PKD.  In Chapter 3, using a genetic approach, 
I explore Hh signaling in ADPKD mouse models jck, Pkd1 cko and Pkd2 cko, on a mixed strain 
background. My data show Hh signaling may play a role in disease progression in most mouse 
models analyzed. In Chapter 4, I investigate initiating mechanisms of renal cystogenesis in Thm1 
cko mice using RNA-Sequencing. My data reveal upregulated STAT3 signaling in pre-cystic 
Thm1 cko kidneys, while in vitro studies using THM1 kd human kidney 293T cells show a 
dysregulated response to IL-6, which activates STAT3 signaling. Taken together, these studies are 




STAT3 in renal cyst initiation, proposing these pathways as therapeutic targets. Several Hh and 






























Chapter Two: Inhibition of Hedgehog signaling suppresses proliferation and 





Previously published as an open access article as: Silva LM, Jacobs DT, Allard BA, Fields TA, 
Sharma M, Wallace DP, et al. Inhibition of Hedgehog signaling suppresses proliferation and 
microcyst formation of human Autosomal Dominant Polycystic Kidney Disease cells [138]. 












Autosomal Dominant Polycystic Kidney Disease (ADPKD) is caused by mutation of 
PKD1 or PKD2, which encode polycystin 1 and 2, respectively.  The polycystins localize to 
primary cilia and the functional loss of the polycystin complex leads to the formation and 
progressive growth of fluid-filled cysts in the kidney.  The pathogenesis of ADPKD is complex 
and molecular mechanisms connecting ciliary dysfunction to renal cystogenesis are unclear.  
Primary cilia mediate Hedgehog signaling, which modulates cell proliferation and differentiation 
in a tissue-dependent manner.  Previously, we showed that Hedgehog signaling was increased in 
cystic kidneys of several PKD mouse models and that Hedgehog inhibition prevented cyst 
formation in embryonic PKD mouse kidneys treated with cAMP.  Here, we show that in human 
ADPKD tissue, Hedgehog target and activator, Glioma 1, was elevated and localized to cyst-lining 
epithelial cells and to interstitial cells, suggesting increased autocrine and paracrine Hedgehog 
signaling in ADPKD, respectively.  Further, Hedgehog inhibitors reduced basal and cAMP-
induced proliferation of ADPKD cells and cyst formation in vitro.  These data suggest that 
Hedgehog signaling is increased in human ADPKD and that suppression of Hedgehog signaling 












Autosomal Dominant Polycystic Kidney Disease (ADPKD) is among the most commonly 
inherited, life-threatening diseases, affecting 1:500 adults worldwide.  ADPKD is characterized by 
the formation and growth of fluid-filled cysts in the kidneys, which compress neighboring tubules, 
resulting in renal injury and fibrosis.  Many of these patients progress to end stage renal disease 
(ESRD) by the 6th decade of life.  The molecular mechanisms underlying ADPKD are complex, 
involving misregulation of multiple signaling pathways and aberration of multiple cellular 
processes, including increased cell proliferation, fluid secretion, apoptosis and incomplete 
differentiation of tubular epithelial cells [35].  Most ADPKD cases result from mutations in PKD1 
or PKD2, which encode polycystin-1 (PC1) and polycystin-2 (PC2) transmembrane proteins, 
respectively.  PC1 and PC2 localize to the primary cilium, a non-motile sensory organelle, and 
form a functional complex that is thought to mediate signaling pathways [39, 139].   
Mutation of most ciliary genes causes renal cystic disease [140]; however, the role of 
ciliary dysfunction in renal cystogenesis remains unclear.  Paradoxically, genetic ablation of 
primary cilia in Pkd1 and Pkd2 conditional knock-out mice attenuated PC-mediated renal 
cystogenesis, which led to the proposal that an undefined cilia-dependent signaling pathway 
promotes PC-deficient cyst formation [58].  Consistent with these data, pharmacological 
shortening of primary cilia in Nek8jck/jck mouse mutants, which model ADPKD, ameliorated 
Nek8jck/jck renal cystic disease [141].   
The Hedgehog (Hh) signaling pathway is among the best characterized ciliary-mediated 
pathways.  Hh signaling controls cell proliferation, differentiation and cell fate, and is essential for 
development and tissue homeostasis [91].  In the canonical pathway, binding of Hh ligand to the 




activation of the Smoothened (SMO) signal transducer [142, 143].  The signal is transduced 
ultimately to the Glioma (GLI) transcriptional factors and final mediators of the pathway, whose 
activity is also regulated at the cilium. 
Cilia are formed by intraflagellar transport (IFT), the bi-directional transport of protein 
cargo along the ciliary axoneme by IFT-B and -A complexes.  In mice, loss of most IFT-B proteins 
causes absent or stunted cilia and the inability to respond to the Hh signal [144].  In contrast, loss 
of the IFT-A proteins, THM1 (TTC21B) and IFT122, results in accumulation of proteins in bulb-
like structures at the distal tip of shortened cilia and enhanced activation of the Hh pathway [25, 
26].. Deletion of Ift-B or -A genes in the kidney or globally during late embryogenesis causes renal 
cysts [107, 121, 145].    
Hh signaling has been reported to promote renal proliferative diseases, including renal cell 
carcinoma [112, 146] and  fibrosis [147], and several studies suggest Hh signaling may also 
influence cystogenesis [80, 108, 148, 149].  Cystic kidneys of several mouse models have shown 
upregulation of Gli1, a transcriptional target of the Hh pathway [80, 107-109], and Hh inhibition 
reduced cAMP-mediated cysts of cultured embryonic kidneys of several PKD mouse models [80].  
Further, a transcriptome analysis of human ADPKD kidneys revealed increased expression of Hh 
signaling components [110].  Thus, we sought to extend our analyses of Hh signaling in renal 
cystogenesis to human ADPKD.  To this end, we examined Hh status in human ADPKD renal 
tissue and primary cystic epithelial cells and assessed the effect of Hh modulators on ADPKD cell 








2.3.1 ADPKD tissue and primary cells 
Human ADPKD and NHK tissues and primary cells were obtained from the PKD 
Biomarkers and Biomaterials Core at the University of Kansas Medical Center (KUMC)[150]. 
ADPKD kidneys were obtained from the KU hospital and hospitals participating in the Polycystic 
Kidney Research Retrieval Program with the assistance of the PKD Foundation (Kansas City, MO) 
and the Biospecimen Shared Resource (BSR) at KUMC.  These kidneys were removed solely for 
clinical purposes and de-identified prior to being submitted to the Repository; therefore, the use of 
the materials is not considered human subjects research. The protocol for the use of ADPKD tissue 
for research was approved by the Institutional Review Board at KUMC.  These patients were below 
the age of 60 years.  Since the majority of the ADPKD cases is caused by mutation in PKD1 and 
has an earlier onset of ESRD compared to patients with PKD2 mutation (54 vs 74 years)[151] all 
of the primary ADPKD cells were likely derived from PKD1-mutant kidneys.  Normal regions of 
human kidneys, confirmed by histological examination, were obtained from nephrectomy 
specimens through the BSR at KUMC.  Normal kidneys withheld from transplantation due to poor 
perfusion characteristics and anatomical abnormalities were obtained from the Midwest Transplant 
Network (Kansas City, KS).  
The protocol used to generate NHK and ADPKD primary renal epithelial cells has been 
detailed previously[50, 152-155].  Samples are retrieved from the renal cortex of NHK individuals 
and from the epithelium of surface (cortical) cysts of ADPKD individuals.  Cells from several 
cysts are pooled together.  Preparative steps, such as collagenase treatment and keeping cell 
passage numbers 2, which collectively keep lines fibroblast-free, are identical between NHK and 




Dolichos biflorus agglutinin, suggesting that most cells derive from collecting ducts [50, 153].  
The Core provides approximately 1-2 million primary cells each of 1 NHK and 1 ADPKD line on 
a weekly basis to investigators.  
 
2.3.2 qPCR  
RNA was extracted using Trizol (Life Technologies) and RNA integrity was verified by 
the Genome Sequencing Facility at the KUMC.  RIN values ranged from 8-10.  One microgram 
of RNA was converted into cDNA using Quanta Biosciences qScript cDNA mix (VWR 
International). The analysis was made using Quanta Biosciences Perfecta qPCR Supermix (VWR 
International) and a BioRad CFX Connect Real-Time PCR Detection System.  Primers used are 
described in Table 2. qPCR was performed on RNA lysates of three ADPKD and three NHK cell 
lines.  
 
2.3.3 Western blot  
Protein extracts were obtained by homogenizing frozen kidney tissue with Passive Lysis 
Buffer (Promega) cointaining proteinase inhibitor cocktail (Pierce) using Bullet Blender Bead 
Lysis tubes (MidSci) and a Bullet Blender Storm 24 (Next Advance) set at Speed 10 for 
approximately 10 minutes, centrifuging lysates at 4°C at maximum speed for 1 minute, and 
collecting the supernatant. Western blot was done as described [80], using primary antibodies for 
GLI1 and βactin (Cell Signaling Technology).  Extracts from six NHK and five ADPKD frozen 






2.3.4 Immunohistochemistry  
Human ADPKD and NHK renal tissue sections were deparaffinized in xylene and 
rehydrated through an ethanol series to distilled water.  Antigen retrieval was performed by 
steaming tissue sections for 25 minutes in Sodium Citrate Buffer (10mM Sodium Citrate (Fisher 
Scientific), 0.05% Tween 20 (Fisher Scientific) in autoclaved water, pH 6.0).  To minimize 
background staining, sections were treated with 3% hydrogen peroxide for 30 min, washed in PBS, 
then blocked with 1% BSA for 1 hour.  Tissue sections were then incubated with GLI1 antibody 
(Cell Signaling) overnight at 4°C.  Following 3 washes in PBS, sections were incubated with HRP-
conjugated rabbit secondary antibody (Cell Signaling) for 30 minutes.  Following another 3 washes 
in PBS, tissues were incubated with ABC reagent (Vector Laboratories), rinsed in PBS, and then 
incubated with SigmaFAST DAB metal enhancer (Sigma) until desired signal/color was obtained.  
To determine GLI1 localization in proximal tubules or collecting ducts, sections were incubated 
with fluorescein-conjugated Lotus tetragonolobulus or Dolichus biflorus agglutinin for 1 hour at 
room temperature, washed and mounted in Vectashield containing 4,6-diamidino-2-phenylindole 
(DAPI) (Vector Laboratories).  Staining was visualized and imaged using a Nikon 80i 
light/fluorescent microscope and Nikon DS-Fi1 camera. Immunohistochemistry images were 
converted to grayscale. 
 
2.3.5 Immunofluorescence 
Cells were then washed with PBS, fixed with 4% paraformaldehyde and 0.2% triton X-100 
for 10 minutes at room temperature, washed with PBS, and blocked with 1% BSA in PBS for 1 
hour, and then incubated with antibodies against SMO (generous gift from Dr. K Anderson, and 




-tubulin (Sigma) overnight at 4° C. To address localization of the SMO within cilia, cells were 
first treated with 500nM SAG (Enzo Life Sciences) in DMSO.  Following 3 washes in PBS, cells 
were incubated with anti-rabbit AF488 and anti-mouse AF594 (InVitrogen Technologies) for 30 
minutes at room temperature. Cells were washed 3X in PBS and mounted with Vectashield 
containing 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories).  Immuno-labeled cells 
were viewed and imaged using a Leica TCS SPE confocal microscope configured on a DM550 Q 
upright microscope.   Each ciliary antibody was examined in a minimum of three NHK and three 
ADPKD cell lines. 
 
2.3.6 Cell Proliferation  
ADPKD or NHK cells (15,000 cells/well) were plated in a 24-well plate (Costar) in 
DMEM/F12 media containing 1% FBS, ITS (Insulin, Transferrin, Selenium) culture supplement 
(Fisher) and Pen/Strep and grown to approximately 70% confluency.  Cells were serum-starved in 
DMEM/F12 media containing 0.02% FBS and Pen/Strep overnight.  The following morning, cells 
were treated with 500nM SAG, 5M Gant 61 or Sant2 (Enzo Life Sciences), 100M cAMP 
(Sigma), 100ng/mL EGF (Sigma), DMSO (Sigma) alone or in combination for 48 hours.  Cells 
were trypsinized in 100l of Trypsin (Gibco), and 10l were counted in a cell counting slide (Bio-
Rad) using a TC20 automated cell counter (Bio-Rad).  Assays were performed in triplicate wells, 
using primary cells from at least three NHK and three ADPKD kidneys.   
 
2.3.7 Viability/Cytotoxicity Assay 
Following the same 48-hour treatment of NHK and ADPKD cells with Hh modulators, 




Viability/Cytotoxicity Kit for mammalian cells (InVitrogen) was used according to manufacturer’s 
instructions.  Cells were imaged using a digital camera attached to an inverted microscope Nikon 
Eclipse TE2000-U.  Assays were performed in duplicate wells, using primary cells from three 
NHK and three ADPKD kidneys.   
 
2.3.8 Microcyst Assay  
ADPKD and NHK cells (4,000 cells/well) were dispersed in cold Type I collagen 
(Advanced Biomatrix; San Diego, CA) in wells of a 96-well plate, warmed to 37°C to enable 
polymerization of the collagen gel.  Defined media (DMEM/F12, Pen/Strep, ITS Culture 
Supplement (Fisher), 5x10-8 M Hydrocortisone and 5x10-12 M Triiodothyronine) supplemented 
with forskolin (5 μM) and EGF (5 ng/ml), to stimulate in vitro cyst formation, was placed onto 
collagen-suspended cells, and refreshed every 2-3 days over a 7-day period.  Once microscopic 
cysts (microcysts) were observed, media was replaced with media containing either forskolin, 
EGF, DMSO (Sigma), 500nM SAG, 5M or 10M Gant 61 or 5M Sant2 (Enzo Life Sciences) 
in combination or individually. For wells treated with Hh modulators alone, wells were incubated 
with defined media for 4h prior to treatment with Hh modulators, to wash out initial EGF and 
forskolin from the collagen matrix. Following microcyst assay, culture gels were fixed in 0.5% 
paraformaldehyde, and microcysts were photographed with a digital camera attached to an inverted 
microscope Nikon Eclipse TE2000-U, objective (2x).  Diameters of spherical cysts with distinct 
lumens were measured using Image-Pro Premier 9.2 64 bit.  Assays were performed in six replicate 







2.4.1 GLI1 is upregulated in human ADPKD renal tissue  
We performed Western blot analysis for GLI1, a target and activator of the Hh pathway.  
We found increased GLI1 in ADPKD compared to normal human kidney (NHK) tissue (Figure 
2.1A; 2.2-2.3).  Using immunohistochemistry, we observed more intense nuclear GLI1 staining in 
interstitial cells and in epithelial cells lining some cysts of ADPKD tissue (Figure 2.1B; Figure 
2.4).  We next incubated ADPKD tissue sections with fluorescein-conjugated Lotus 
tetragonolobulus (LTL) or Dolichos biflorus agglutinin (DBA) lectins or with antibody against 
Tamm-Horsfall Protein (THP) to examine the tubular origin of GLI1+ cells.   While cystic cells 
did not label with LTL, a marker of proximal tubules, DBA or THP staining of cystic cells 
suggested that the cysts originated from collecting duct or Loop of Henle tubules, respectively, 





































Figure 2.1: GLI1 is upregulated in human ADPKD renal tissue  
A) Western blot analysis for GLI1 in normal human kidney (NHK) and ADPKD extracts of the 
renal cortex. Bars (mean  SEM) are band intensity normalized to β-actin, and represented as fold 
change from NHK, set to 1.0.  Quantification of GLI1 levels was performed on 6 NHK and 5 
ADPKD tissue extracts (Table 1).  Statistical significance was determined by an unpaired t-test.  
*P<0.05   B) Immunohistochemistry for GLI1 on NHK and ADPKD sections of the renal cortex.  











































Figure 2.2: GLI1 is upregulated in human ADPKD renal tissue.  
 Full-length Western blots of Fig 1. Extracts of mouse embryonic kidney (MEK) were included as 
a positive control for GLI1 detection.  Twice as much MEK extract was loaded in lane 1 than in 
lane 8.  A) 1-minute exposure for GLI1. B) 0.5-second exposure for ß-actin.  C) 40-second 
exposure for ß-actin.  Longer exposure of ß-actin reveals presence of band in MEK extract lane 1.  
This low ß-actin expression indicates markedly higher GLI1 expression in mouse embryonic 


























Figure 2.3: GLI1 is upregulated in human ADPKD renal tissue.  
 Full-length Western blots of extracts of NHK and ADPKD renal tissue, and mouse embryonic 
kidney (MEK), included as a positive control for GLI1 detection.  A) 1-minute exposure for GLI1.  
ADPKD sample 6 appears degraded, and therefore, was not included in the GLI1 quantification in 
Fig 1A.  B) 0.5 second exposure for ß-actin.  Absence of ß-actin bands in MEK lanes indicates 













Figure 2.4: GLI1 immunohistochemistry on ADPKD tissue.   
GLI1 immunohistochemistry with no GLI1 antibody control.  Images obtained with a 40X 










Figure 2.5: GLI1-expressing epithelial cells derive from collecting duct and Loop of Henle 
tubules  
GLI1 immunohistochemistry and staining with DBA, LTL and THP on ADPKD sections of the 








Figure 2.6: GLI1 immunohistochemistry on ADPKD tissue.  
GLI1 immunohistochemistry with no GLI1 antibody control.  Images obtained with a 20X 




2.4.2 Ciliary trafficking and Hedgehog signaling are intact in ADPKD primary renal 
epithelial cells 
In mice, ciliary length appears to affect PKD severity [58, 141].  Further, increased ciliary 
length has been reported in the Pkd1RC/RC mutant mouse, which harbors an ADPKD mutation [29], 
and in Pkd1-/- and Pkd2-/- - derived embryonic renal epithelial cells [55].  Since ciliary length can 
be modified via IFT, and IFT affects Hh signaling [144], we examined ciliary localization of IFT 
components in primary epithelial cells derived from the cortex of NHK kidneys or from surface 
cysts of ADPKD kidneys.   The majority of NHK and ADPKD primary renal epithelial cells 
stained with varying intensities for DBA, but not for LTL or THP (Figure 2.7-2.8), suggesting 
most cells originate from collecting ducts, consistent with previous reports [50, 153].  In ADPKD 
primary cells, IFT-B components, IFT52, IFT81 and IFT88, and IFT-A component, IFT140, 
localized throughout the cilium, similar to their localization in NHK cells (Figure 2.9).   
The BBSome is an 8-unit protein complex that shuttles protein cargo to cellular membranes 
and throughout the ciliary membrane and has been suggested to regulate the ciliary import and 
export of PC1 and PC2.  Bbs1 knock-down or expression of a dominant-negative form of Bbs3 in 
IMCD cells resulted in absence of PC1 in the cilium [156], while combined deficiency of BBS4 
and BBS5 in retinal pigment epithelial (RPE) cells caused ciliary accumulation of PC2 [157].  To 
determine if the BBSome is conversely affected in ADPKD, we examined the localization of BBS 
components, BBS2 and BBS5 (Figure 2.9).  Similar to the IFT proteins, the BBS proteins localized 
normally along the ciliary axoneme.  Together, these data suggest that polycystin dysfunction does 
not overtly affect the ciliary trafficking machinery.   
We examined Hh status in ADPKD primary renal epithelial cells.  Using qPCR, we found 




Additionally, we examined SMO localization, which enriches in the cilium upon pathway 
stimulation [142].  In the absence of Hh agonist, SMO was mostly undetected in primary cilia of 
NHK and ADPKD cells, but following treatment with SAG, a SMO agonist, NHK and ADPKD 
cells showed similar ciliary enrichment of SMO (Figure 2.10B), suggesting similar Hh signaling 
levels.  These data indicate that ADPKD primary renal epithelial cells have Hh signaling 









Figure 2.7: NHK and ADPKD primary renal epithelial cells are DBA-positive.    
Representative staining of primary renal epithelial cells with DBA, marker for the collecting duct.  























Figure 2.8: NHK and ADPKD primary renal epithelial cells are DBA-positive.    
Representative staining of primary renal epithelial cells with LTL together with immunostaining 
for THP, which are markers of proximal tubule, and Loop of Henle, respectively.  Staining was 







Figure 2.9: Primary cilia of ADPKD cells show normal localization of IFT and BBS proteins  
Immunofluorescence for IFT52 (green), IFT81 (green), IFT88 (green), IFT140 (green), BBS2 
(green), and BBS5 (green) and acetylated α-tubulin (red) in NHK and ADPKD cells.  Scale bar = 
25 m.  Localization of each ciliary protein was examined in a minimum of 3 NHK and 3 ADPKD 






Figure 2.10: Human primary renal epithelial cells have Hh signaling machinery  
A) qPCR analysis on NHK and ADPKD primary renal epithelial cells.  Bars represent mean  
SEM of 3 NHK and 3 ADPKD cell lines (Table 1). B) Immunofluorescence for SMO (green) and 
acetylated α-tubulin (red) in presence or absence of SAG.  Experiments were replicated in 5 NHK 









2.4.3 Hh inhibitors reduce cAMP-induced proliferation and microcyst formation of human 
primary ADPKD renal cells 
Since Hh signaling affects proliferation of multiple cell types, we examined proliferation 
of ADPKD cells in response to Hh modulators.  NHK and ADPKD cells were treated with SAG 
or with SMO or GLI antagonists, Sant2 or Gant61, respectively, alone or in combination with 
SAG, for 48 hours.  Cell counts were then obtained.  As control, cells of designated wells were 
treated with epidermal growth factor (EGF), which increases proliferation of both NHK and 
ADPKD cells[158] (Figure 2.11).  In both NHK and ADPKD cells, SAG increased proliferation, 
and Gant61 and Sant2 reduced proliferation (Figure 2.11).  Additionally, treatment with SAG 
together with either Gant61 or Sant2 reduced proliferation relative to SAG (Figure 2.11), 
suggesting specificity of the Hh modulators.   
In ADPKD cells, but not in NHK cells, cAMP is mitogenic [159].  To determine if Hh 
inhibitors can mitigate cAMP-mediated proliferation, NHK and ADPKD cells were treated with 
cAMP in the presence of DMSO or a Hh modulator.  As control in all experiments, cells of 
designated wells were treated with EGF or cAMP ascertaining that NHK and ADPKD cells 
increased proliferation in response to EGF and that ADPKD cells increased proliferation in 
response to cAMP (Figure 2.12). In NHK cells, cAMP, cAMP with DMSO, or cAMP with SAG, 
did not alter cell proliferation, but treatment with cAMP together with Gant61 or Sant2 reduced 
proliferation (Figure 2.12).  In ADPKD cells, cAMP increased proliferation, and cAMP with 
DMSO showed similar proliferation as cAMP alone.  Treatment with cAMP and SAG yielded 
similar cell counts as treatment with cAMP and DMSO (Figure 2.12), suggesting that SAG does 
not increase cAMP-mediated proliferation.  However, cAMP together with either Gant61 or Sant2 




Gant61 or Sant can offset cAMP-induced proliferation. Using a Viability/Cytotoxicity Assay that 
incorporates calcein AM in live cells (GFP) and ethidium homodimer-1 in dead cells (RFP), we 
observed that treatment of NHK and ADPKD cells with Hh modulators, alone or together with 
cAMP, resulted in similar proportions of live and dead cells as non-treatment, indicating that the 
Hh modulators did not cause cell death (Figure 2.13).  Together, these data demonstrate that Hh 
signaling can modulate proliferation of both NHK and ADPKD epithelial cells, and moreover, that 
Hh inhibition can counter the mitogenic effect of cAMP in ADPKD cells. 
Finally, we examined the effect of Hh modulation on microcyst formation of ADPKD and 
NHK cells.  Microcyst formation was initiated by treatment with forskolin (FSK), which is a cAMP 
agonist, and EGF, which has an established role in promoting proliferation in ADPKD.  Once 
microcysts were observed, cysts were treated with SAG, Gant61 or Sant2, alone or in combination 
with FSK and EGF.  Continued treatment with FSK and EGF following microcyst initiation caused 
maximal cyst formation and growth in NHK (64.312.37 cysts/experiment with average cyst 
surface area of 18.5  3.93 mm2) and ADPKD cells (83.0  16.39 cysts/experiment with average 
cyst surface area of 46.6  21.86 mm2) (Figure 2.14; Figure 2.15), while treatment with Hh 
modulators alone did not influence cyst formation or growth (data not shown).  SAG together with 
FSK and EGF resulted in similar cyst number and size as FSK and EGF treatment, suggesting 
SAG does not exacerbate FSK and EGF-induced cyst growth (Figure 2.14).  Conversely, treatment 
with Gant61 or Sant2 together with FSK and EGF, markedly reduced number and size of 
microcysts relative to FSK and EGF-treated cells (Figure 2.14).  These data suggest that while Hh 
signaling is insufficient to induce cyst formation and growth, inhibition of Hh signaling within a 









Figure 2.11: Hh inhibitors suppress proliferation of human primary renal epithelial cells  
A) Percent cell proliferation of NHK and B) ADPKD cells.  Cell proliferation was calculated as a 
proportion relative to cell number of the NT (no treatment) group, which was set at 100. NT-no 
treatment; EGF – epidermal growth factor; SAG – Smoothened agonist; SANT2- Smoothened 
antagonist; GANT61 – GLI antagonist.  Bars represent mean  SEM of 5 NHK and 4 ADPKD cell 
lines (Table 1).  Cells of each line were plated in triplicate wells.  Statistical significance was 












Figure 2.12: Hh inhibitors counteract proliferative effect of cAMP in human ADPKD 
primary renal cells  
A) Percent cell proliferation of NHK and B) ADPKD cells.  NT-no treatment; EGF – epidermal 
growth factor; SAG – Smoothened agonist; SANT2- Smoothened antagonist; GANT61 – GLI 
antagonist.  Bars represent mean  SEM of 3 NHK and 3 ADPKD cell lines (Table 1).  Cells of 
each line were plated in triplicate wells.  Statistical significance was determined by ANOVA and 



























































               


















     
               




                   

































Figure 2.13: Analysis of cell viability and cytotoxicity of Hh modulators.   
NHK and ADPKD cells were treated with Hh modulators, alone or together with cAMP, then 
analyzed for viability/ retention of calcein AM (GFP) in membranes or for non-
viability/incorporation of ethidium homodimer-1 (RFP) in nuclei.  NT - no treatment.  Methanol 
– 30-minute incubation in 70% methanol was used to cause 100% cell death.  Hh treatments were 
imaged using a 2X objective lens.  Scale bar for 2X – 500μm.  Scale bar for 10X - 100μm.  Assays 





































Figure 2.14: Hh inhibitors suppress microcyst formation of human primary renal epithelial 
cells   
A) Representative images of NHK and ADPKD microcysts in the presence of DMSO or Hh 
modulators.  Cysts were imaged and quantified using Image-Pro Premier.  Gant61-5 – Gant61 at 
5M; Gant61-10 – Gant61 at 10 M.  Scale bar = 500m.  B) Quantification of microcysts.  Cyst 
size was calculated as a proportion relative to average cyst size of FSK and EGF treatment group, 
which was set at 100.  FSK-forskolin.  Bars represent mean  SEM of 3 NHK and 4 ADPKD cell 
lines (Table 1).  Cells of each line were plated in six replicate wells.  Statistical significance was 






          
 
 
Figure 2.15: Hh inhibitors reduce FSK- and EGF-induced cyst growth.   
Quantification of total microcyst surface area per well.  FSK-forskolin.  Bars represent mean  
SEM of 3 NHK cell lines and 4 ADPKD cell lines.  Cells of each line were plated in six replicate 







Table 1: Sample numbers used in experiments. 
   
    NHK ADPKD 
Figure 1 Tissue 1 K235 K389 
  Tissue 2 K241 K294 
  Tissue 3 K395 K397 
  Tissue 4 K364 K288 
  Tissue 5 K378 K399 
  Tissue 6 K388   
        
Figure 3 IFT52 K340 K315 
    K388 K276 
    K376 K354 
  IFT81 K347 K428 
    K362 K276 
    K376 K315 
  IFT88 K376 K276 
    K265 K251 
    K337 K315 
  IFT140 K340 K276 
    K376 K315 
    K419 K417 
  BBS2 and BBS5 K340 K276 
    K388 K354 
    K419 K417 
  BBS5 K376 K315 
        
 Figure 4 qPCR K337 K315 
    K340 K354 
    K388 K426 
  SMO K376 K339 
    K337 K288 
    K340 K276 
    K347 K428 




                             
    NHK ADPKD 
Figure 5 proliferation K291 K276 
    K337 K319 
    K340 K339 
    K342 K346 
    K419   
        
Figure 6 cAMP proliferation K250 K276 
    K340 K319 
    K342 K339 
        
Figure 7 microcyst assay K340 K276 
    K342 K348 
    K362 K350 
      K354 
        
Figure S5 DBA/LTL/THP K340 K441 
    K419 K386 
    K325 K315 
    K337 K339 
    K343 K417 
        
Figure S6 Live/Dead Assay K340 K348 
    K337 K339 
    K388 K386 
                                            
            


































The primary cilium is important for renal tubular integrity, but the mechanisms by which 
ciliary dysfunction causes or modifies renal cystogenesis are not understood.  Multiple 
mechanisms may lead to a renal cyst, and these may compare or contrast among different renal 
cystic diseases. ADPKD causes enlarged kidneys with varying degrees of fibrosis and ESRD in 
the mid-50s, while non-PKD renal cystic diseases often reduce kidney size due to abundant fibrosis 
and cause ESRD in the pediatric years.  In ADPKD, cilia lack polycystin but are thought to be 
structurally intact, while in non-PKD cystic kidney disease, cilia structure is often disrupted due 
to mutation of a ciliary structural component.  Cilia regulate Hh signaling, and this pathway is 
often altered in cilia mouse mutants with or without an overt ciliary structural defect[23, 25, 26, 
160-162].  Since others have reported increased Gli1 in cystic kidneys of ciliary mutants, Ift140 
and Arl13B conditional knock-out mice[107, 109], and we have observed increased Gli1 in cystic 
kidneys of Nek8jck/jck, Thm1 and Pkd1 conditional knock-out mice (on mixed strain backgrounds) 
[80], suggesting a general role for elevated Hh signaling in renal cystogenesis, we investigated the 
Hh pathway in human ADPKD.   
Previously, a transcriptome analysis of human ADPKD renal tissue revealed increased 
expression of Hh components, PTCH1, GLI2 and GAS1 [110].  Our data showing enhanced 
staining of nuclear GLI1 in interstitial and epithelial cells of ADPKD cystic tissue add to this.  
Renal tubular epithelial cells have been reported to express Hh ligand [147], thus the presence of 
GLI1 in both interstitial and epithelial cells suggests occurrence of paracrine and autocrine Hh 
signaling mechanisms in ADPKD.  Paracrine and autocrine Hh signaling have been reported in 
other kidney pathologies. Increased paracrine Hh signaling was demonstrated in renal fibrosis 




intact Hh signaling we observed in NHK and ADPKD primary renal epithelial cells also supports 
the presence of autocrine signaling.  This is consistent with studies in IMCD cells, demonstrating 
GLIS2 as a negative regulator of Hh signaling [149] and showing reduced ciliary GPR161, a Hh 
negative modulator, in response to SAG [51], collectively indicating that the Hh signaling 
machinery is present in kidney epithelial cells.  We anticipated increased Hh signaling in ADPKD 
primary renal epithelial cells similar to ADPKD renal tissue.  This was not the case, which could 
reflect that additional cell types or signaling molecules cross-talk in vivo to cause upregulation of 
GLI1.  Indeed, a caveat of in vitro systems is the inability to mimic all conditions present in vivo.  
Yet, in vitro models can be useful in understanding how cells might respond to a particular 
stimulus, and the primary renal epithelial cells allow functional analyses on patient-derived 
materials, which cannot be done at the tissue level.   
Our data show that Hh inhibitors can abate cAMP-mediated proliferation in ADPKD cells 
and FSK and EGF-induced cystogenesis in vitro.  Previously, we observed that Gant61 and Sant2 
reduced the cAMP-mediated cystogenic effects in cultured mouse embryonic kidneys [80].  
Collectively these data suggest that Hh signaling is a necessary component of cAMP-mediated 
proliferation and cystogenesis in these systems.  In human ADPKD cells, elevated intracellular 
cAMP activates cystic fibrosis transmembrane conductance regulator (CFTR)-mediated Cl- 
secretion and B-Raf/MEK/ERK signaling, causing fluid secretion and increased proliferation of 
cyst-lining epithelial cells, respectively [49, 52].  ADPKD cells have low homeostatic intracellular 
Ca2+, which causes the mitogenic effect of cAMP, while augmenting intracellular Ca2+ in ADPKD 
cells counters this effect [51].  Hh inhibition may mitigate the proliferative and cystogenic effects 
of cAMP, FSK and EGF, by possible crosstalk between Hh and ERK signaling, which has been 




inhibitor, GCD-0449, has been shown to increase steady-state levels of intracellular Ca2+ in a lung 
cancer cell line [165].  Similarly, Hh inhibition might also increase intracellular Ca2+ in kidney 
epithelial cells. 
Alternatively, Hh signaling and polycystin function might intersect at the primary cilium.  
PC2 has been indicated to be part of a complex in the cilium with adenylyl cyclases 5 and 6, and 
phosphodiesterase 4C, which synthesize and catabolizes cAMP, respectively, likely regulating 
cAMP at the primary cilium.   Advanced imaging technology has enabled visualization of ciliary 
pools of Ca2+ and cAMP [40, 53].  In mouse embryonic fibroblasts, Hh activation increased ciliary 
Ca2+ [40], and decreased ciliary cAMP [53].  These studies also demonstrated that ciliary and 
intracellular pools of Ca2+ and cAMP are distinct.  Since Hh inhibition by GDC-0449 increased 
intracellular Ca2+ in a lung cancer cell line [164],  Hh activity may have opposing effects on ciliary 
and intracellular Ca2+.  Thus, regulation of Hh signaling on ciliary and intracellular Ca2+ requires 
further investigation.    
SAG alone, but not SAG with cAMP, increased proliferation of NHK cells.  This may 
suggest that cAMP countered the effect of SAG and inhibited Hh signaling in these cells.  Yet 
treatment with the Hh inhibitors together with cAMP reduced cell proliferation relative to cAMP 
with DMSO, suggesting that proliferation of NHK cells may require a certain level of Hh signaling, 
which was inhibited by Gant61 and Sant2.  In mouse PKD kidneys, which have high levels of 
cAMP, GLI1 is increased indicating enhanced Hh signaling [80].  Thus, while cAMP might 
dampen the Hh pathway in certain contexts, this dampening effect may be overridden in the PKD 
setting.   
Two studies have documented increased ciliary length in Pkd models [29, 55], which 




BBSome components in several ADPKD cell lines indicates that the ciliary trafficking machinery 
is not affected by polycystin dysfunction.  Thus, other mechanisms may account for the increased 
ciliary length reported in these Pkd models.  Polymorphisms in the mouse strain background may 
interact with the Pkd mutation to increase cilia length.  These polymorphisms might reside in genes 
that regulate ciliary structure [140], cAMP [59], cytosolic tubulin, actin machinery [162], or other 
factor that can modulate cilia length.  These genes would represent PKD modifiers. 
Aside from IFT, epigenetic regulation can also result in increased GLI levels.  Epigenetics 
has been shown to affect PKD in a preclinical model, and cancer studies have linked epigenetics 
to Hh regulation.  Inhibition of Brd4, a BET bromodomain protein and epigenetic regulator, 
attenuated PKD progression in a Pkd1 conditional knock out mouse [166].  In addition, treatment 
of a medulloblastoma mouse model with I-BET151, a Brd4 inhibitor, reduced Gli1 expression, 
cell proliferation and tumor growth, indicating epigenetics drives Hh activation in cancer [167].  
GLI1 may be a target of BRD4 in ADPKD as well.   
Since some, but not all, cyst-lining epithelial cells in ADPKD renal tissue showed increased 
nuclear GLI1 staining, and increased Gli1 transcripts have been evident in kidneys of mouse 
models that were already cystic [80, 107, 109], we speculate that Hh signaling may increase with 
disease progression, and that patients with more advanced ADPKD might show a greater increase 
in Hh signaling than those with earlier disease.  Importantly, Hh inhibitors countered the 
proliferative and cystogenic effects of cAMP/forskolin in patient-derived renal epithelial cells.  
Our findings suggest clinical relevance of the Hh pathway in ADPKD.  An important experiment 
will be to examine whether Hh inhibition attenuates disease in an appropriate Pkd model in vivo.  
Hh inhibition may also serve to attenuate fibrosis[147], which is a significant component of 




feedback loops may also be present.  Thus, targeting more than one pathway at different disease 
stages might be most effective.  Interestingly, Hh and ERK signaling have been demonstrated to 
work cooperatively in some cancers, with inhibition of one pathway showing modest effect, but 
simultaneous inhibition of both pathways having a synergistic effect [168-170].  Exploring similar 
possibilities in appropriate Pkd models in vivo may help determine effective combinatorial 












































3.1 Abstract  
ADPKD is among the most common fatal genetic diseases, yet therapy is limited and a 
cure is lacking.  Proteins disrupted in ADPKD localize to the primary cilium, an antenna-like 
sensory organelle that mediates signaling pathways.  While primary cilia dysfunction appears 
central to renal cystogenesis, molecular mechanisms are only beginning to emerge.  Previously, 
we showed that downregulation of the ciliary-mediated Hh pathway attenuated renal cystic disease 
in mice mutant for Thm1, a ciliary gene and negative regulator of Hh signaling, and reduced 
cystogenic potential of cultured embryonic kidneys of ADPKD mouse models, jck and Pkd1 
mutants, suggesting a general role for increased Hh signaling in renal cystogenesis.  Here we 
examined whether inhibition of the Hh pathway can attenuate renal cystogenesis in jck mutant, 
and Pkd1 and Pkd2 conditional knock-out mice in vivo.  In jck mice, increased expression of GLI1, 
a Hh target and reporter of the Hh pathway, correlated with disease progression, and genetic 
inhibition of the pathway reduced kidney weight/body weight (KW/BW) ratios and BUN levels. 
Additionally, genetic inhibition of the Hh pathway reduced KW/BW ratios of Pkd1 conditional 
knock-out (cko) mice. These data suggest Hh signaling may play a role in disease progression of 











Autosomal Dominant Polycystic Kidney Disease (ADPKD) affects ~1:500 individuals 
worldwide and is characterized by progressive growth of renal cysts that can lead to end-stage 
renal disease by the 6th decade of life [6]. ADPKD is caused by mutations in PKD1 or PKD2, 
which encode polycystin-1 (PC1) and polycystin-2 (PC2) proteins, respectively. These proteins 
form a complex that localizes to primary cilia [139].  
Primary cilia are sensory organelles that are synthesized and maintained by intraflagellar 
transport (IFT) or the bi-directional transport of proteins along a microtubule-based axoneme.  
Mutation of most Ift genes causes misregulation of the Hh pathway [25, 26, 144].  Further, 
mutation of most Ift and ciliary genes results in renal cystic disease [107, 121, 140, 145].  
Paradoxically, genetic removal of cilia in ADPKD orthologous mouse models and 
pharmacological shortening of cilia in Nek8jck/jck mice attenuated PKD, leading to the proposition 
that a cilia-dependent signaling pathway promotes cyst formation [56, 58, 97, 141].   
The mammalian Hedgehog (Hh) signaling pathway is cilia-dependent [91] and has been 
reported to be elevated in several renal diseases, including renal fibrosis [147], renal cell carcinoma 
[112, 146], and renal cystic diseases [80, 108, 148, 149]. Hh signaling is activated by ligand 
binding to the Patched (PTCH) receptor, leading to the ciliary enrichment and activation of the 
Smoothened (SMO) signal transducer and to the ultimate activation of the GLI transcription 
factors (GLI1, GLI2 or GLI3)  [93, 97-99].  In human ADPKD kidneys, expression of Hh signaling 
components was increased [110, 138], and in cystic kidneys of five ADPKD mouse models, 
including Nek8jck/jck mutants and Pkd1 conditional knock-out mice, expression of Gli1, a Hh target 




reduced renal cystogenic potential of cultured embryonic kidneys of Nek8jck/jck and Pkdm1Bei/m1Bei 
mice [80].  Here I have sought to extend these analyses in vivo and downregulated Hh signaling in 
Nek8jck/jck mutants and Pkd1 and Pkd2 conditional knock-out mice. 
 
3.3 Methods  
3.3.1 Generation of jck mutant and Pkd1 and Pkd2 conditional knock-out mice 
jck+/- mice were obtained from David Beier. Gli2+/- mice were obtained from Jonathan 
Eggenshwiler, courtesy of Alexandra Joyner.  Gli2flox/flox, Pkd1flox/flox, Pkd2flox/flox and ROSA26-Cre 
mice were obtained from Jackson Laboratories (Stock numbers 007926, 010671, 017292 and 
004847, respectively). Mice were intercrossed on a mixed FVB, SV129 and C57BL/J background. 
ROSA26-CreERT/+ and Gli2 floxed alleles were introduced into the lines to generate jck+/-;Gli2 
flox/flox, Pkd1flox/flox; Gli2flox/flox or Pkd2flox/flox; Gli2flox/flox females to mate to jck+/-; Gli2+/-; ROSA26-
CreERT/+, Pkd1flox/+; Gli2+/-, ROSA26-CreERT/+ or Pkd2flox/+; Gli2+/-, ROSA26-CreERT/+ males.  jck, 
Gli2flox/fox (at P0), Pkd1flox/flox, Gli2flox/flox (at P2) and Pkd2flox/flox, Gli2 flox/flox (at P0) nursing mothers 
were injected with tamoxifen (Sigma) at 10mg/40g mouse body weight to induce gene deletion in 
pups.  
Since the PKD field prefers a pure strain background and to reduce variability between 









3.3.2 Mouse Genotyping 
Mouse genotypes were determined using polymerase chain reaction (PCR) of tail genomic 
DNA. Primer sequences and PCR product sizes are listed in Table 3.  PCR amplicon generated by 
jck primers required digestion with BseYI at 37°C for 5h and 50 min.  
 
3.3.3 Kidney Weight/Body Weight measurements  
Mouse body weight and individual kidneys were weighed in grams using a standard 
weighing scale. Total kidney weights were divided by body weight for each mouse. 
 
3.3.4 q-PCR 
Trizol (Life Technologies) was used to extract RNA, according to manufacturer’s protocol. 
One microgram of RNA was converted to cDNA using Quanta Biosciences qScript cDNA 
Supermix (VWR International). Quantitative PCR analysis was performed using Quanta 
Biosciences Perfecta qPCR Supermix (VWR International) and a Bio-Rad CFX Connect Real-
Time PCR Detection System. Primers sequences are listed in Table 4. Primers were designed using 
the Roche Applied Science RT-qPCR Assay Design Center and synthesized by IDT Technologies.  
 
3.3.5 BUN measurements 
Mouse trunk blood was collected into Microvette CB 300 Blood Collection System tubes 
(Kent Scientific), and centrifuged at 1800g at 4°C for 8 minutes to collect serum. BUN was 







Kidneys were extracted and renal capsules were removed. Kidneys were bisected 
longitudinally and fixed in Bouin’s solution for several days. Tissue was dehydrated through an 
ethanol series, followed by xylene, and embedded in paraffin. Sections of 8μm were obtained using 
a microtome.  Sections were deparaffinized in xylene and rehydrated through an ethanol series to 
distilled water and stained with hematoxylin and eosin.  
 
3.3.7 Immunohistochemistry 
 Bisected kidneys were fixed in 4% paraformaldehyde for 3-7 days, then placed in 70% 
ethanol.  Tissues were processed, embedded in paraffin, sectioned and rehydrated as described 
above (3.3.6). Antigen retrieval was performed by steaming tissue sections for 25 minutes in 
Sodium Citrate Buffer (10 mM Sodium Citrate, 0.05% Tween 20, pH 6.0). To minimize 
background staining, sections were treated with 3% hydrogen peroxide for 30 min, washed in PBS, 
then blocked with 1% BSA for 1 hour. Cells were then incubated with GLI1 antibody (1:100 
dilution) (Cell Signaling) overnight at 4°C. Following 3 washes in PBS, sections were incubated 
with HRP-conjugated rabbit secondary antibody (Cell Signaling) for 30 minutes. Following 
another 3 washes in PBS, tissues were incubated with ABC reagent (Vector Laboratories), rinsed 
in PBS, and then incubated with SigmaFAST DAB metal enhancer (Sigma) until desired 
signal/color was obtained. Staining was visualized and imaged using a Nikon 80i microscope 







3.3.8 Drug studies 
Small molecule Hh inhibitors, GDC-0449 and Itraconazole, were administered to jck and 
nursing Pkd1 females.  GDC-0449 (50mg/kg and 100mg/kg; LC laboratories) and Itraconazole 
(100mg/kg; Selleckchem) were reconstituted to 50mg/ml or 100mg/ml in 10% ethanol;10% 
cremophor;80% saline (Sigma). A 5x stock was generated weekly and diluted daily to 1x prior to 
administering the i.p. injection. The dose was calculated based on body weight. jck and control 
mice were injected every day with GDC-0449 or for 5 days/week with Itraconazole from P21 to 
P49.  Pkd1flox/flox nursing moms were injected with Itraconazole every other day, from P6 to P23, 
to deliver treatment to Pkd1 cko offspring. Following treatment, mice were sacrificed and kidneys 
were examined.  
 
3.4 Results 
3.4.1 Hh activity correlates with disease progression in jck mutant mice on a pure C57BL6/J 
background 
Previously, we found Gli1 was increased in 7-week-old jck mutants on a mixed strain 
background [80].  To reduce variability between experiments, we backcrossed our jck mice onto a 
C57BL6/J background to the 10th generation and expanded our analysis to determine if increased 
Hh signaling activity correlates with disease progression in jck mutants on this background. We 
harvested kidneys from control and jck mutant mice at 7, 13 and 18 weeks of age.  Increased 
%KW/BW and BUN levels in older mutants confirmed that renal function declines progressively 
(Figure 3.1a,b). We next performed real time PCR analyses for Gli1, Gli2 and Gli3.  Our results 
show 18-week-old mutant kidneys have significantly increased Gli1 and Gli3 expression, 




target genes, these results suggest Hh activity may increase with disease progression (Figure 3.1c).  
Additionally, immunohistochemistry revealed increased nuclear expression of GLI1 in epithelial 
cells lining the cysts and in cells within the interstitium of 18-week-old mutant kidneys (Figure 
3.1d), indicating increased autocrine and paracrine Hh signaling, respectively. These combined 











































Figure 3.1: Hh activity correlates with disease progression in jck mutant mice  
A) %KW/BW and B) BUN levels of control and jck mutants at 7, 13 and 18 weeks of age. C) 
qPCR for Gli1, Gli2 and Gli3 for control and jck mutant kidneys at 7- (N=3 controls, N=6 jck), 
13- (N=3 controls; N=3 jck) and 18- (N=5 controls, N=3 jck) weeks of age. D) Representative 
images of control and jck mutants at 7, 13 and 18 weeks of age (N=3 each group). Statistical 










3.4.2 Genetic downregulation of Hh signaling reduced renal cystogenesis in jck mice 
We downregulated the Hh pathway in jck mice by deleting Gli2, the main transcriptional 
activator at P0 on a mixed strain background.  At 7 weeks of age, jck,Gli2 mutants showed fewer 
renal cysts and reduced renal size, relative to jck single mutants (Figure 3.2a). These data indicate 
that decreasing Hh signaling reduces renal cystogenesis. Additionally, jck,Gli2 mutants showed 
significant reduction in kidney weight/body weight ratios (KW/BW) (Figure 3.2b). Furthermore, 
in the few animals tested so far, there is a trend for jck,Gli2 mutants to show lower blood urea 
nitrogen (BUN) levels, suggesting downregulation of Hh signaling may improve kidney function 



















                                                                                     


















Figure 3.2: Genetic downregulation of Hh signaling reduced renal cystogenesis in jck mice 
A) Representative images of whole-mount and histological sections of kidneys from 7-week-old 
control, jck/jck  and jck/jck;Gli2 cko mice.    B) KW/BW ratios.  C) BUN of 7-week-old control, 
jck/jck, jck/jck,Gli2 het and jck/jck;Gli2 mutant mice (N≥7). Statistical significance was 










3.4.3 Genetic downregulation of Hh signaling reduced %KW/BW in Pkd1 conditional knock-
out mice  
Genetic downregulation of Hh signaling by conditionally deleting Gli2 in orthologous 
mouse models of ADPKD also reduced KW/BW ratios in the Pkd1,Gli2 double knock-outs, 
compared to Pkd1 mutants on a mixed strain background (Figure 3.3a). These data indicate Hh 
signaling may also play a role in renal cystic disease in Pkd1 cko mouse model.  
The KW/BW ratios of Pkd2,Gli2 double mutants appeared similar to that of the Pkd2 cko 





































Figure 3.3: Genetic downregulation of Hh signaling (Hh) reduced %KW/BW in Pkd1 but 
may not have reduce %KW/BW in Pkd2 mutants 
A) %KW/BW for control, Pkd1 cko, Pkd1 cko,Gli2 het and Pkd1,Gli2 cko mice.  B) %KW/BW 
for control, Pkd2 cko, Pkd2 cko,Gli2 het and Pkd2,Gli2 cko mice. Statistical significance was 








3.4.4 Pilot experiments with Hh inhibitors, GDC-0449 and Itraconazole  
We sought to recapitulate the genetic experiments pharmacologically using two Hh 
inhibitors, GDC-0449 (50mg/kg and 100mg/kg) and Itraconazole (100mg/kg). GDC-0449 is the 
first FDA-approved Hh inhibitor and Itraconazole is a FDA-approved antifungal drug.  Both drugs 
inhibit SMO [116, 164]. Mice were treated daily with GDC-0449 or 5 days/week with 
Itraconazole, from P21 to P63, at which time animals were dissected. Treatments with Hh 
inhibitors did not reduce KW/BW of jck mutants (Figure 3.4a-d), but further investigation is 
required to determine if the conditions reduced Hh signaling activity.   
We also treated control and Pkd1 mutant mice with Itraconazole.  Deletion of Pkd1 was 
induced at P2, resulting in rapidly progressing renal cystic disease. We administered 
intraperitoneal injections of either vehicle or Itraconazole every other day to the nursing female 
from P6 until P23.  Since Itraconazole has been reported in human breast milk, we speculated that 
the drug would be delivered through the breastmilk to the nursing progeny [171]. At P23, KW/BW 
ratios were similar between saline- and Itraconazole-treated mutants (Figure 3.5a,b).  Additionally, 
Gli1 expression was also similar between saline- and Itraconazole-treated mutants, suggesting that 







































Figure 3.4: Hh inhibitors did not reduce %KW/BW in jck mutant mice  
A)  Timeline for GDC-0449 treatment. Control and mutant animals were treated with saline (N≥3 
each group) or with GDC-0449 at 50mg/kg (N≥4 each group) or GDC-0449-2x at 100mg/kg (N≥3 
each group). B) %KW/BW for GDC-0449 treated animals. C) Timeline for Itraconazole at 
100mg/kg treatment. For the Itraconazole studies, N≥5 each group. D) %KW/BW for Itraconazole-










Figure 3.5: Itraconazole did not reduce %KW/BW in Pkd1 mutant mice  
A) Timeline for Itraconazole treatment. B) Pkd1 cko were treated with saline (N=2) or with 
Itraconazole (N=5) through breast milk.  C) qPCR for control and mutant mice treated with saline 
































































3.5 Discussion  
The mechanisms connecting primary cilia dysfunction to renal cystogenesis are not well 
understood.  The Hh signaling pathway is the best characterized, cilia-mediated pathway, so we 
have hypothesized that misregulation of Hh signaling has a role in renal cystogenesis.  Previously, 
increased Hh signaling was reported in human ADPKD kidneys [110, 138] and in cystic kidneys 
of several mouse models, including Thm1 cko, jck and Pkd1 cko [80, 107, 109]. Furthermore, 
downregulation of Hh signaling reduced renal cystogenesis of Thm1 cko mice and of cultured jck 
and Pkd1-mutant mouse embryonic kidneys [80]. In the current studies, we expanded on the role 
of Hh signaling in renal cystogenesis of jck, Pkd1 cko and Pkd2 cko mice. Our preliminary data 
suggest increased Hh signaling correlates with disease progression in jck mutant mice and that 
genetic downregulation of the pathway decreases KW/BW ratios in jck and Pkd1 cko mouse 
models. 
The influence of mouse strain background on PKD severity [172-175], due to genetic 
modifiers interacting with the causal mutation [172], is an on-going discussion in the field. An 
advantage of working with a mixed strain background is better representation of the genetic 
heterogeneity of the human population. However, a disadvantage is the phenotypic variability that 
can ensue, requiring larger numbers of animals in order to obtain significance. The cpk, pcy and 
jck mutants are among the PKD mouse models that showed less severe disease on a C57BL/6J 
genetic background, compared to other background strains [175-177]. Consistent with these 
findings, in the current studies we show that 7-week- old jck mutants on a mixed background have 
higher %KW/BW, compared to jck mice on a C56BL/6J background at the same age, indicating 
disease is likely less severe in jck mice under a pure C57BL/6J background. Also, Gli1 expression 




week-old mice under a mixed background already have elevated Gli1 expression [80]. 
Interestingly, these results further support a role for enhanced Hh activity in disease progression. 
Efforts are ongoing to increase the number of animals in the experimental groups.  
Recently, we have backcrossed all lines onto a C57BL/6J background to the 10th generation, and 
crosses are underway to obtain single and double cko mice. Since our data on jck mice seem 
promising, we are continuing to examine the effect of deletion of Gli2 in the jck mice.  
Furthermore, for Pkd1 and Pkd2 mice, we have generated lines to delete Smo, which may provide 
greater downregulation of the Hh pathway, than deletion of Gli2, since there is redundancy 
between the GLI transcription factors.  
Our data show enhanced nuclear GLI1 staining in renal interstitial and epithelial cells of 
jck cystic tissue on a pure C57BL/6J background. Since renal tubular epithelial cells have been 
shown to express Hh ligand, the presence of GLI1 in the interstitium and in the epithelia suggests 
active paracrine and autocrine Hh signaling in this mouse model [147].  Interestingly, elevated 
paracrine Hh signaling has been reported in renal fibrosis, while increased autocrine Hh signaling 
has been shown in renal cell carcinoma (RCC) [112, 147].  Perhaps the paracrine Hh signaling in 
jck mice reflects or contributes to fibrosis, while the autocrine Hh signaling plays a role in 
proliferation of renal epithelial cells. Since Hh activity appeared to increase with disease 
progression and epithelial cells of non-dilated tubules in jck mutant mice did not show nuclear 
GLI1 staining, increased Hh signaling may have a role in disease progression, but not initiation.  
Previously, genetic downregulation of Hh signaling by deleting Gli2 attenuated renal 
cystogenesis in Thm1 conditional knock-out mice [80]. Our data show that genetic downregulation 




and % KW/BW in Pkd1 conditional knock-out mice, on a mixed strain background. These findings 
suggest increased Hh signaling may have a general role in renal cystogenesis.  
Pharmacological Hh inhibitors reduced the cAMP-mediated cystogenic effects in cultured 
mouse embryonic kidneys [80] and also reduced cAMP-mediated cell proliferation of ADPKD 
primary cells [138], and thus, we anticipated that administration of pharmacological inhibitors of 
Hh signaling would attenuate renal cystogenesis in jck and Pkd1 mutant mice, which was not the 
case. However, we cannot exclude the possibility that Hh pathway was not sufficiently inhibited. 
Thus, dosing and timing of treatment will need to be adjusted.  
How Hh signaling connects to known mechanisms underlying ADPKD is unclear. ADPKD 
cells have decreased intracellular calcium, which together with aberrant cAMP activity induces 
cyst growth by stimulating fluid secretion and cell proliferation  [49, 52]. Importantly, restoring 
calcium concentrations prevented cAMP-mediated cell proliferation of ADPKD cells in vitro [51].  
A study suggests that Hh signaling may modulate intracellular Ca2+. Smo inhibitor, GDC-0449, 
increased intracellular Ca2+ in a cancer cell line and reduced proliferation in vitro [164]. The 
mechanism(s) that lead to increased Hh activity in PKD is also not clear. Gli1 was shown to be a 
target of Brd4, an epigenetic regulator, in a medulloblastoma mouse model [178], and inhibition 
of Brd4 in Pkd1 cko mice slowed cystic disease progression [166]. Thus, epigenetics may be a 
mechanism modulating Hh signaling in the PKD mouse models used in this study. 
In summary, our data suggest downregulation of the Hh pathway may attenuate renal cystic 
disease in ADPKD mouse models. This together with our findings that Hh signaling is increased 
in human ADPKD tissue and that Hh inhibitors reduced cell proliferation and microcyst formation 
of culture human ADPKD renal epithelial cells [138] (Chapter 2), suggest Hh signaling can be 




approved or are currently under clinical trials for cancer therapy, repurposing available drugs could 
be an option [111].  Since ADPKD involves dysregulation of several pathways, inhibiting more 
than one pathway and possibly targeting different pathways at different disease stages will likely 
provide a more effective therapy. Our work suggests a role for ciliary-mediated Hh signaling in 
disease progression. What primary cilia-mediated mechanisms lead to disease initiation is another 






























RNA sequencing reveals increased STAT3 signaling in pre-cystic kidneys of 
















 Primary cilia are sensory organelles that mediate signaling pathways, and dysfunction of 
primary cilia leads to renal cystic disease.  Multiple cellular and signaling aberrations contribute 
to renal cystic disease, while initiating molecular mechanisms remain unclear.  In mice, perinatal 
global deletion of ciliary gene, Thm1, causes renal cysts beginning at P15.  To identify molecular 
events that initiate renal cystogenesis in Thm1 conditional knockout (cko) mice, RNA sequencing 
was performed on total RNA of pre-cystic and cystic kidneys of Thm1 cko mice at P9 and P42, 
respectively.  We reasoned that genes with significantly altered expression in both pre-cystic and 
cystic kidneys would represent early initiation events leading to cystogenesis.  Approximately 10 
genes - Fos, Jun, Stat3, Endothelin 1, Vcam1, Complement C3, Ccl2, Egr2, and Adcy7- met this 
criterion.  This gene set included genes typically expressed not just by epithelial cells, but by 
endothelial or immune cells.  Western blot analysis on whole kidney extracts showed increased P-
STAT3 at P10, and upregulation of multiple components of STAT and EDN1-MAPK signaling 
pathways at P42.  Additionally, immunohistochemistry revealed increased nuclear localization of 
P-STAT3 in epithelial cells of non-dilated and dilated tubules and cysts, and in interstitial cells. 
To study the connection between primary cilia dysfunction and upregulated STAT3 signaling, we 
generated THM1 knock-down (kd) human renal 293T clonal cell lines.  THM1 kd cells have 
shortened primary cilia with IFT81 accumulation in a bulb-like structure at the distal tip, indicative 
of a retrograde ciliary protein trafficking defect.   Upon treatment with IL6, THM1 kd cells showed 
a more robust second wave of STAT3 activation than control cells, which was preceded by a more 
intense activation of ERK.  Together, these data suggest that altered gene expression and signaling 
in renal epithelial, vascular and immune cells may potentiate renal cystogenesis, and, in particular, 





Primary cilia are signaling organelles essential for development and health [80, 140]. 
Genetic mutations that disrupt primary cilia function lead to ciliopathies, which manifest a plethora 
of clinical features, among which renal cystic diseases are very common [140].  The most common 
renal cystic disease is Autosomal Dominant Polycystic Kidney Disease (ADPKD), affecting 
~1:500 individuals worldwide.  ADPKD is caused by mutations in PKD1 and PKD2, encoding 
polycystin-1 and polycystin-2, which function as a heterocomplex in primary cilia [6, 139]. Thus 
far, molecular mechanisms identified in ADPKD appear to contribute to disease progression, while 
initiating events remain largely obscure.  Intriguingly, while ciliary dysfunction leads to renal 
cystogenesis, genetic ablation of primary cilia in orthologous ADPKD mouse models and 
pharmacological reduction of cilia length in Nek8jck/jck mice ameliorated the renal cystic disease, 
suggesting a ciliary-mediated signaling pathway is essential for cyst development [56, 58, 97, 141].   
Primary cilia are synthesized and maintained via intraflagellar transport (IFT) or the bi-
directional transport of protein cargo along a microtubular axoneme.  IFT is mediated by two 
protein complexes: IFT complex B interacts with the kinesin motor to mediate anterograde IFT, 
while IFT complex A together with cytoplasmic dynein is required for retrograde IFT. IFT-A 
proteins are also essential for ciliary import of signaling molecules [179].  In mice, deletion of Ift-
A or -B genes either perinatally or specifically in the kidney results in renal cystic disease [107, 
121, 145].  However, Ift-A and –B mutants usually show contrasting ciliary phenotypes and can 
also show opposing signaling phenotypes, reflecting differing roles of IFT-A and –B in 
ciliogenesis and in regulating signaling pathways [25, 26, 107, 144].  Thus, study of both Ift mutant 




Thm1 (TPR-containing Hedgehog modulator 1; also termed Ttc21b) encodes a component 
of IFT complex A, and its deletion impairs retrograde IFT, causing accumulation of proteins in 
bulb-like distal tips of shortened primary cilia [25].  Causative and modifying mutations in THM1 
have been identified in 5% of patients with ciliopathies, including NPHP, BBS, MKS and Jeune 
Syndrome [82]. In mice, deletion of Thm1 recapitulates many of the clinical manifestations of 
these ciliopathies, and perinatal global deletion of Thm1 results in renal cystic disease with renal 
tubular dilations beginning by P15 [25, 80].  By P42, Thm1 cko renal cystic disease shares 
similarities with ADPKD, including increased cAMP and increased cell proliferation.  Thm1 cko 
cystic kidneys also show enhanced Hh signaling, a ciliary dependent pathway [80], which we and 
others have shown to be misregulated in ADPKD renal cystic tissue. In the current study, we 
sought to determine the signaling molecules and pathways that initiate renal cystogenesis in the 
Thm1 cko mouse, using a global transcriptomics approach.  
 
4.3 Methods 
4.3.1 Generation of Thm1 cko mice 
Thm1 cko mice were generated as described [80]. Briefly, a Thm1-lacZ knockout mouse 
(Ttc21btm2a(KOMP)Wtsi) was purchased from KOMP (Knockout Mouse Project) [80].  The LacZ gene 
was flanked by Frt sites in intron 3 of Thm1, and loxP sites flanked exon 4 of Thm1.   Thm1-lacZ 
mice were mated to FLPeR mice, expressing FLPe recombinase, to flip out the LacZ gene, and 
allow transcription from exon 3 to exon 4.  Resulting Thm1flox/+ mice were intercrossed to 
generate Thm1flox/flox mice. A tamoxifen-inducible ROSA26CreERT mouse (Jackson Laboratory – 
stock 004847) was mated to Thm1aln/+mice to create Thm1aln/+; ROSA26CreERT/+ mice. 




and 3, nursing females were injected intraperitoneally (i.p) with tamoxifen (Sigma) at 10 mg/40g 
mouse body weight to delete Thm1 globally. 
 
4.3.2 Mouse genotyping 
Genotyping primers are listed in Table 5. The aln PCR product was digested with AvaII at 
45 °C for 1h. 
 
4.3.3 Kidney Weight/Body Weight measurements  
Mouse body weight and individual kidneys were weighed in grams using a standard 
weighing scale. Total kidney weights were divided by body weight for each mouse. 
 
4.3.4 RNA seq 
 RNA was extracted from whole kidneys of P9 and P42 control and Thm1 cko mice (N=6/ 
each group), using QIAGEN RNeasy Mini kit according to manufacturer’s instructions.  Samples 
with RIN values >8.0, determined by the KUMC Genomics Core, were used for RNA Sequencing 
(HiSeq2500, Ilumina). 100-cycle paired-end reads were performed (HiSeq2500, llumina), 
assigning 6 multiplexed samples/lane, providing 44X coverage/sample. Data were analyzed by Dr. 
Sumedha Gunewardena of the KUMC Bioinformatics Core.  Sequences were aligned to the mouse 
genome (GRCm38). Differential gene expression was calculated using Cuffdiff, and P-values were 







4.3.5 Western Blot 
Protein extracts were obtained by homogenizing frozen kidney tissue with Passive Lysis 
Buffer (Promega) containing proteinase inhibitor cocktail (Pierce) using 0.5 mm zirconium oxide 
PINK beads (Next Advance) and a Bullet Blender Storm (Next Advance) set at Speed 10 for 
approximately 10 minutes. Lysates were centrifuged at 4°C at maximum speed for 1 minute and 
supernatant was collected. Western blot was performed as described [80], using primary antibodies 
for P-STAT3, STAT3, P-ERK, ERK, P-CJUN, C-FOS, FOS-B, STAT5, STAT6, STAT1 and P-
Cyclin D1 (Cell Signaling Technology), Endothelin-1 (Thermo Scientific) and VCAM1 (Abcam).  
Extracts from three controls and three mutants at P10 and at P42 were examined. Western Blot 
was quantified using ImageJ. 
 
4.3.6 Immunohistochemistry 
Kidneys were dissected and renal capsules removed.  Kidneys were bisected longitudinally 
and placed in 4% paraformaldehyde for 3-7 days, then placed in 70% ethanol in PBS.  Tissues 
were dehydrated through an ethanol series, embedded in paraffin and sectioned at 8µm thicknesses.  
Tissue sections were deparaffinized in xylene and rehydrated through an ethanol series to distilled 
water.  Antigen retrieval was performed by steaming tissue sections for 25 minutes in Sodium 
Citrate Buffer (10mM Sodium Citrate, 0.05% Tween 20, pH 6.0).  To minimize background 
staining, sections were treated with 3% hydrogen peroxide for 30 min, washed in PBS, then 
blocked with 1% BSA for 1 hour.  Tissues were then incubated with P-STAT3 antibody (Cell 
Signaling) overnight at 4°C.  Following 3 washes in PBS, sections were incubated with HRP-
conjugated rabbit secondary antibody (Cell Signaling) for 30 minutes.  Following another 3 washes 




incubated with Sigma FAST DAB metal enhancer (Sigma) until desired signal/color was obtained.  
Staining was visualized and imaged using a Nikon 80i light/fluorescent microscope and Nikon 
DS-Fi1 camera.  
 
4.3.7 Drug studies  
To inhibit STAT3 signaling pharmacologically, STAT3 inhibitors, Pyrimethamine 
(Sigma), Stattic (Tocris) and C188-9 (Sigma), were used.  Treatments began around weaning (P21) 
and were administered until dissection at P42. Daily gavages of pyrimethamine was administered 
at two doses - 12.5mg/kg and 25mg/kg.  Control (N=2) and Thm1 cko mice (N=1) received 
12.5mg/kg pyrimethamine. Control (N=1) and Thm1 cko mice (N=3) received 25mg/kg 
pyrimethamine. Control (N=3) and Thm1 cko mice (N=3) received vehicle.  Intraperitoneal 
injections of Stattic (10mg/kg) was administered every other day to control (N=4) and Thm1 cko 
mice (N=3), while vehicle was administered to control (N=1) and Thm1 cko mice (N=4). Lastly, 
daily intraperitoneal injections of C188-9 (50mg/kg) was administered to Thm1 cko mice (N=4), 
while vehicle was administered to a Thm1 cko mouse (N=1). 
 
4.3.8 Immunofluorescence  
Cells were washed with PBS, fixed in 4% paraformaldehyde containing 0.2% triton X-100 
for 10 minutes at room temperature, washed with PBS, and blocked with 1% BSA in PBS for 1 
hour, and then incubated with antibodies against IFT81 (Proteintech) and acetylated -tubulin 
(Sigma) overnight at 4° C.  Following 3 washes in PBS, cells were incubated with anti-rabbit 
secondary antibody conjugated to AF488 and anti-mouse secondary antibody conjugated to AF594 




mounted with Vectashield containing 4,6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories).  Immuno-labeled cells were viewed and imaged using a Leica TCS SPE confocal 
microscope configured on a DM550 Q upright microscope.    
 
4.3.9 Cell culture  
 THM1 knock-down (kd) using shRNA was performed as described [25].  Briefly, pLKO.1-
THM1-R1 plasmid was generated by cloning oligonucleotide THM1 R1 (Table 5) annealed to its 
5′-phosphorylated complementary strand into the AgeI/EcoRI sites of the pLKO.1 lentiviral 
vector.  Subsequently, 293T cells were transfected with plasmids VSVG, delta8.2 and pLKO.1-
THM1-R1 (pLKO.1 served as the empty control vector) for 48 h using FuGENE (Roche) to 
generate viruses. Medium containing the lentiviruses was filtered (0.45 μm pore size) and target 
239T cells were infected with lentiviruses expressing either empty control vector or THM1 R1 
shRNA using Polybrene. Cells were then trypsinized and selected in medium containing 
puromycin. Lastly, clonal cell lines were generated by isolating single colonies using sterile 
cloning disks (Fisher), and expanding colonies. 
Recombinant human IL-6 (PeproTech) was dissolved in 0.1% BSA.  Control and THM1 
kd 293T renal cell lines were grown in 6-well cell culture plates until about 90% confluency. Cells 
were treated with IL6 (20ng/ml) for different durations (0.5h, 1h, 2h, 3h, 4h, 8, 12h, 16h and 24h). 
Cells that were non-treated (NT) or cultured with 0.1% BSA for 24h wells were considered 
controls. Cell pellets were collected at the end of each timepoint, protein was extracted, and 







4.4.1 Expression of genes typically expressed by epithelial, endothelial or immune cells is 
increased in pre-cystic kidneys of Thm1 cko mice  
To uncover the misregulated genes and pathways that initiate Thm1-deficient renal 
cystogenesis, RNA sequencing was performed on pre-cystic and cystic whole kidney RNA extracts 
of Thm1 cko mice, at P9 and P42, respectively. We hypothesized that genes with altered expression 
both before renal cysts have formed and during disease progression may contribute to cyst 
initiation as well as progression, while genes that are misregulated at P42, but not before cysts 
have formed, may contribute to disease progression.  We identified approximately 10 genes that 
were significantly increased at P9 and further increased at P42.  These genes included Fos, Jun, 
Stat3, ET1, Vcam1, Ccl2, C3, Egr2 and Adcy7.  We noted that while Fos, Jun and Stat3 are 
expressed by the renal epithelium, ET1 and Vcam1 are often associated with endothelium, and 
Ccl2, C3, Egr2 and Adcy7 are thought to be expressed by immune cells (Figure 4.1a). These data 
suggest that in our global Thm1 cko mouse, alteration of gene expression and signaling in renal 
epithelial, vascular and immune cells may potentiate renal cyst formation.   
In contrast to the small gene set that was upregulated in both pre-cystic and cystic kidneys, 
P42 cystic tissues showed more than 5000 misregulated genes.  In accordance with increased 
expression of Fos, Jun and Stat3, in the gene set described above, multiple genes of the STAT 
(Signal Transducer and Activator of Transcription) and MAPK (Mitogen-activated protein kinase) 
signaling pathways were increased.  Additionally, genes of the Hedgehog (Hh) signaling pathway, 
Ptch2 and Gli3, and of Notch signaling, Notch3 and Jag1, were also increased in cystic kidneys 
(Figure 4.1b). Sufu, a negative Hh regulator, was decreased, consistent with increased Hh 




integrin, FGF, Wnt and TGF-ß signaling pathways were increased (Figure 4.1b).  In contrast, 
multiple mitochondrial genes were downregulated.  These data illustrate the molecular complexity 


























Figure 4.1: Genes and signaling pathways significantly increased in Thm1 cko kidneys 
A) Genes significantly upregulated in both pre-cystic and cystic kidneys of P9 and P42 Thm1 cko 







4.4.2 Increased STAT3 may promote renal cystogenesis in Thm1 cko mice  
 To validate the RNA Seq data, we performed Western Blot analysis on pre-cystic (P10) 
and cystic (P42) whole kidney extracts. We used antibodies for Endothelin-1, p-ERK, ERK, c-
JUN, c-FOS and FOSB, which are components of the Endothelin-MAPK signaling pathway [180, 
181] but quantification of the blot did not show a significant elevation of MAPK components 
amounts in pre-cystic kidneys (data not shown); indicating MAPK signaling may not play a role 
in renal cyst initiation in this mouse model. As expected, all the MAPK pathway components we 
probed for are increased in P42 kidneys, including a significant increase in FOS-B (data not 
shown), when renal cystic disease is already advanced (Figure 4.2a). In addition, we used 
antibodies for several STAT proteins (STAT1, 3, 5 and 6 are shown for P42 kidneys, while 3 and 
5 are shown for P10 kidneys) and observed that these STATs are increased in cystic kidneys. 
Importantly, STAT3 activation (P-STAT3/STAT3) is prominently increased in pre-cystic kidneys, 
suggesting a role for this pathway in renal cyst initiation in this mouse model (Figure 4.2b).  
Further, we show increased levels of P-Cyclin D1 [182] and of inflammatory molecule, VCAM1 
[183], in cystic kidneys (Figure 4.2a). Because P-STAT3/STAT3 ratios are significantly increased 
in pre-cystic and cystic Thm1 cko kidneys (Figure 4.2b), we next examined subcellular localization 
of P-STAT3 in tissue sections. Nuclear localization of P-STAT3 indicates activation of the 
pathway [184]. We observed increased nuclear P-STAT3 in renal epithelial cells of non-dilated 
and dilated tubules at 20, and in cystic-lining epithelial cells and interstial cells at P42 (Figure 
4.2c).  Together, these results suggest STAT3 and MAPK signaling may initiate renal cystogenesis 









Figure 4.2: MAPK and STAT3 signaling upregulation may promote renal cystogenesis in 
Thm1 cko mice  
A) Western Blot analysis shows slight increase in P-CJUN and increased STAT3 activation in pre-
cystic kidneys at P10. Cystic kidneys show increase in MAPK signaling components and increased 
STAT1, 3 and 6. B) Western Blot quantification show increased P-STAT3/STAT3 in pre-cystic 
and cystic Thm1 cko kidneys. WB was quantified using ImageJ. C) Immunohistochemistry for P-
STAT3 on P20 and P42 control and Thm1 cko kidney sections. Red arrows point to increased 
nuclear P-STAT3 in epithelial cells of non-dilated and dilated tubules at P20, and in interstitial 







4.4.3 IL-6 treated THM1 kd 293T human renal cells show a stronger second wave of STAT3 
activation that is preceded by increased activation of ERK 
 To determine the molecular mechanism by which STAT3 signaling is upregulated by the 
Thm1 ciliary defect, we generated clonal THM1 kd 293T human renal cells, with 70% less THM1 
protein control cells (Figure 4.3a).  THM1 kd 293T cells have shortened cilia with accumulation 
of IFT81 in bulb-like distal tips, indicative of a retrograde IFT defect (Figure 4.3b).  A previous 
report showed that IL6 treatment of colon cancer, adenocarcinoma and 293T cells caused two 
waves of STAT3 activation.  The first wave induced EGF expression, which then induced the 
second wave of STAT3 activation [185].  Similarly, we treated control and THM1 kd 293T cells 
with IL6 and examined STAT3 activation at different timepoints. Relative to control cells, THM1 
kd cells showed a more robust second wave of STAT3 activation, which was preceded by a more 
robust activation of ERK (Figure 4.3c-d).  These data demonstrate that THM1 deficiency causes 

















































Figure 4.3: IL6-treated THM1 kd 293T cells show a more robust second wave of STAT3 
activation  
A) Western Blot for THM1 on control and Thm1 kd extracts. B) Analysis of cilia by 
immunostaining for IFT81 (green) and acetylated -tubulin (red). C) Western Blot for P-
STAT3/STAT3 and P-ERK/ERK on extracts of IL6-treated cells (N=2). D) Western blot 
quantification for P-STAT3/STAT3 include BSA and IL6 treatments (1,2,4,12 and 16h) and show 









4.4.4 Treatment of Thm1 cko mice with STAT3 inhibitors  
 To demonstrate a functional role for STAT3 signaling in Thm1 cko renal cystic disease, 
we have attempted pilot experiments with several STAT3 inhibitors - Pyrimethamine at two doses 
(12.5mg/kg and 25mg/kg) [186], Stattic at 10mg/kg [187] and C188-9 at 50mg/kg [188].  These 
STAT3 inhibitors were chosen since pyrimethamine treatment of adult Pkd1 cko mice suppressed 
cyst formation and growth [186], while Stattic attenuated renal disease in a mouse model of Alport 
syndrome [187, 189]. Finally, C188-9 was recently identified and shown to reduce STAT3 
signaling in a mouse model of hepatocellular carcinoma [190]. Administration of pyrimethamine 
or Stattic to Thm1 cko mice did not reduce % KW/BW (Figures 4.4 b,d,f), and also did not reduce 
P-STAT3/STAT3 ratios (Figures 4.4 b,d,f).  C188-9 decreased P-STAT3:STAT3 levels by about 
18-46%, but did not reduce %KW/BW relative to the vehicle-treated Thm1 cko mouse (Figure 4.4 
f).   However, this vehicle-treated Thm1 cko mouse showed relatively higher levels of THM1, and 
an unusually low %KW/BW ratio, suggesting that this vehicle-treated Thm1 cko mouse may not 
be the best representative to compare with the treated mice. Thus, more animals are required to 
























Figure 4.4: Pilot experiments with STAT3 inhibitors  
A/C/E) WB for P-STAT3 and THM1 for Pyrimethamine (PYR), Stattic and C188-9 treated mice. 


































 We performed RNA sequencing in pre-cystic and cystic kidneys of Thm1 cko mice to 
determine molecular mechanisms by which primary cilia dysfunction initiates renal cystic disease.   
We reasoned that genes misregulated in both pre-cystic and cystic kidneys may initiate renal cystic 
disease.  Our data revealed genes often associated with the epithelium (Fos, Fosb, Jun, Junb, 
Stat3), with the endothelium (Endothelin1 and Vcam1), and with the immune system (Ccl2, 
Complement C3, Egr2 and Adcy7), to be upregulated in pre-cystic and cystic kidneys.  These data 
suggest that misregulation of genes in these 3 compartments may initiate disease processes in this 
ciliary mouse model.  These genes may also be initially expressed in renal epithelial cells, which 
has been reported for Ccl2 [131]. Western blot analysis and immunohistochemistry suggest that 
STAT3 signaling is the most prominent pathway upregulated in pre-cystic Thm1 cko kidneys.   
Many of the molecules and pathways that are misregulated in pre-cystic (and cystic) Thm1 
cko kidneys have been reported to contribute to renal cystic disease progression, but not initiation. 
Increased MAPK and STAT3 signaling have been reported in mouse models of ADPKD and in 
human ADPKD tissue [51, 80, 107-109, 138, 184, 186, 191-193].  Endothelin 1 (ET1) is an 
endothelium-derived vasoconstrictor and pro-fibrotic peptide and its overexpression caused renal 
cysts in mice, while rat models of PKD and human ADPKD kidneys show increased ET1 [194-
199]. VCAM1 is an endothelial adhesion molecule that contributes to inflammation in PKD [183]. 
Further, increasing in vitro and in vivo evidence suggest a role for the immune system in PKD 
progression [183, 200-202].  Complement C3 was found to be upregulated in urine of ADPKD 
patients and inhibiting C3 in a mouse model of ADPKD reduced disease progression [203]. Ccl2, 
which encodes monocyte chemoattractant protein 1 (MCP1), is the only molecule which has been 




Ccl2 expression is increased in renal tubular epithelial cells, promoting macrophage recruitment 
and inflammation. Ccl2 expression is regulated by a ciliary-localized protein complex and hence 
is dependent on primary cilia [131].  
Since increased STAT3 activation in pre-cystic Thm1 cko kidneys was the most prominent 
alteration among the proteins we queried, we focused our attention on this pathway. STAT3 is a 
developmental pathway with important roles in cell proliferation and in the immune system. 
Canonical activation of STAT3 signaling occurs when ligands, such as cytokines and growth 
factors, activate Janus kinases (JAK-tyrosine kinases), which in turn phosphorylate and activate 
STAT3, which stimulates transcription of target genes [204]. STAT3 signaling is highly active in 
developing kidneys, suggesting a role in renal development [184].  
Increased STAT3 signaling contributes to cell proliferation and immune response in 
ADPKD progression, but its role in renal cyst initiation has not been reported.  In the interstitium, 
cytokine IL-10 is released by macrophages in ADPKD and activates STAT3, contributing to 
disease progression [205]. In the epithelium, epidermal growth factor (which is upregulated in 
ADPKD) can activate STAT3.  Further, STAT3 activation is increased in ADPKD human tissues 
[205, 206]. How STAT3 signaling leads to renal cystogenesis in our mouse model is unclear. 
Recently, PC1 was found to interact with Liver Kinase B1 (LKB1), a tumor suppressor kinase, 
which is part of a protein complex that localizes to cilia.  This PC1-LKB1 signaling is thought to 
keep Ccl2 expression levels low and thereby regulate inflammation through primary cilia [131].   
Pkd1,Ccl2 dko mice showed reduced renal cystogenesis, suggesting the immune reaction triggered 
by Ccl2 may link primary cilia to renal cystic disease [131]. In a prostate cancer study, Ccl2 was 
shown to be a target of STAT3 signaling [207]. Similarly, STAT3 signaling may also activate Ccl2 




To determine whether increased STAT3 signaling promotes renal cystogenesis in Thm1 
cko mice, we attempted pilot studies using three pharmacological STAT3 inhibitors that have been 
reported to be effective in attenuating disease in mouse models. Pyrimethamine suppressed cyst 
formation and growth in an adult Pkd1 cko mouse model [186]. Stattic decreased STAT3 activity 
and improved renal phenotype in a mouse model of Alport syndrome, a renal disease caused by 
mutation in collagen type IV [187, 189]. Finally, C188-9 reduced STAT3 signaling in a mouse 
model of hepatocellular carcinoma [190].  Our administration of pyrimethamine and Stattic did 
not reduce STAT3 signaling in Thm1 cko kidneys in our pilot studies, and therefore, a.higher 
dosage may be required. C188-9 reduced Stat3 signaling in Thm1 cko kidneys, but was not 
effective in attenuating disease.  However, since our vehicle-treated Thm1 cko mouse showed mild 
cystic kidney disease and relatively high levels of THM1, we propose to expand our animal 
numbers and increase dose of C188-9.  Alternatively, genetic downregulation of STAT3 signaling 
can also be performed [208].  
To investigate the molecular mechanisms by which the Thm1 defect causes upregulation 
of STAT3 signaling we generated THM1 kd 293T renal cells.  Cultured cell lines have both 
disadvantages and advantages.  Cell lines do not allow for the cross-talk that may occur among 
different cell types and/or organs that may lead to pathway misregulation in vivo, and also do not 
represent a specific timepoint in vivo. Nonetheless, in vitro experiments allow for molecular 
analyses that may be difficult to carry out in vivo, and can reveal molecular aberrations that can be 
subsequently correlated with in vivo findings.  We treated control and THM1 kd cells with IL6, a 
cytokine that activates STAT3 signaling [204], and saw an aberrant response in THM1 deficient 
cells, with a stronger second wave of  STAT3 activation preceded by a robust activation of ERK. 




to DNA to activate gene transcription [210], but may also prevent nuclear translocation [209]. P-
CJUN, a component of MAPK signaling, is slightly increased in kidneys of pre-cystic Thm1 cko 
mice, so reduced Thm1 levels may affect regulation of ERK, and in turn, STAT3. Since P-CJUN 
levels were not upregulated in all pre-cystic Thm1 cko kidneys examined, we speculate that this 
increase may be specific to certain cell types, and thus upregulation of MAPK signaling may be 
obscured in whole kidney extracts.  
Another mechanism that may modulate STAT3 signaling in Thm1 deficient cells is via 
PC1. PC1 regulates STAT3 activity by a dual mechanism - through JAK2 or activating STAT3 
within the nucleus [206]. STAT6 is another member of JAK/STAT signaling that has been linked 
to PKD and can also be co-activated by PC1 [211] and localizes to cilia [211]. In contrast, the 
connection between STAT3 signaling and primary cilia is not known.  
In addition to ERK and PC1, other components that are overexpressed in pre-cystic kidneys 
may also activate STAT3 signaling. For instance, ET1 induces secretion of IL6 in osteoblast-like 
cells [212]. Similarly, increased ET1 may induce IL6 in Thm1 deficient kidneys, which would 
activate STAT3 signaling. Immune cells, such as monocytes and macrophages, can also activate 
STAT3 signaling in different cell-types by releasing IL6 [213]. Accordingly, macrophages are 
present in early renal cystic disease in Han:SPRD rats, a model of ADPKD [43]. The presence of 
macrophages in Thm1 cko kidneys can also be examined. 
Finally, cAMP, which is increased and has aberrant activity in ADPKD [49], activates ERK 
signaling, consequently inducing cell proliferation [50]. Thus, cAMP, which is also elevated in 
Thm1 cko cystic kidneys, may also contribute to increased ERK and STAT3 activity in this model 
[80]. Future in vitro studies could examine the effects of cAMP on cell proliferation of THM1 kd 




STAT3 inhibitors to determine whether STAT3 or ERK is the first pathway to be dysregulated in 
THM1 kd cells, and which pathway induces greater cell proliferation, which is essential for cyst 
formation [50].     
In conclusion, our studies expand on the role of primary cilia in renal cyst initiation. Our 
analyses have led us to focus on STAT3 signaling. Future investigations will determine if STAT3 
activation is mediated by primary cilia, the molecular mechanism underlying increased STAT3 
signaling, and ultimately, identification of potential therapeutic targets to prevent renal cyst 




































5.1.1 A role for increased Hedgehog signaling, a ciliary-dependent pathway, in ADPKD 
progression  
An outstanding question in the PKD field is: What are the ciliary-mediated pathways that 
contribute to PKD? In Chapter 2, we are the first to show Hedgehog signaling, a ciliary-dependent 
pathway, plays a role in human ADPKD progression. Expression of Hh signaling components is 
increased in ADPKD mouse models and in human renal tissue [80, 107-110], but a functional role 
for increased Hh signaling in PKD had not been shown. In Chapter 2, we show enhanced nuclear 
GLI1 staining in interstitial and cyst-lining epithelial cells in human ADPKD renal tissue, 
indicating increased paracrine and autocrine Hh signaling, respectively.  Increased GLI1 levels 
were not evident in cultured human ADPKD cells, thus I speculate that cross-talk with other cell 
types or signaling molecules may cause upregulation of GLI1 observed in renal sections.  Renal 
epithelial cells have been reported to release Hh ligands and activate Hh signaling in fibroblasts, 
inducing fibrosis [147], and macrophages have been reported to release and activate Hh signaling 
in an autocrine fashion in the liver [214]. Since fibrosis and macrophages have been reported to 
contribute to ADPKD progression, future investigation can examine whether fibroblasts and 
macrophages contribute to increased Hh signaling in ADPKD.  Further, human ADPKD primary 
renal epithelial cells showed intact ciliary localization of IFT and BBS proteins, and intact response 
to SAG, an activator of Hh signaling. IFT modulates ciliary length and primary cilia are elongated 
in ADPKD mouse models [29, 57]. Our data suggest ciliary trafficking is not compromised in 
ADPKD primary cells.  Thus, changes in ciliary length in vivo may derive from genetic modifiers 




Further, to investigate a functional role for Hh activity, I treated NHK and ADPKD primary 
renal epithelial cells with Hh modulators. Hh inhibitors decreased basal and cAMP-mediated 
proliferation and FSK- and EGF-induced cystogenesis of ADPKD cells.  We previously observed 
that Hh inhibitors reduced the cAMP-mediated cystogenic effects in cultured mouse embryonic 
kidneys [80], and speculate that Hh signaling is a necessary component of cAMP-mediated 
proliferation and cystogenesis in these systems. SAG, a Hh/SMO agonist, increased proliferation, 
but this effect was not observed when NHK cells were treated with SAG and cAMP, suggesting 
that cAMP, which can inhibit the pathway by inducing GLI3 processing [215], may have countered 
the effect of SAG in NHK cells.  However, since Hh activity and cAMP are both increased in 
cystic kidneys of ADPKD mouse models [80], we speculate that the regulation of cAMP on Hh 
signaling is altered in a diseased state.   
Importantly, increased nuclear GLI1 expression was not observed in all cyst-lining 
epithelial cells in ADPKD renal tissue, suggesting that Hh signaling may contribute to disease 
progression, and not initiation.  
 To further demonstrate a functional role for increased Hh signaling in ADPKD, in Chapter 
3, I downregulated Hh signaling [93] genetically in ADPKD mouse models, jck, Pkd1 and Pkd2 
[69, 216].  My data suggest that downregulation of the Hh pathway attenuates disease, decreasing 
%KW/BW of jck, Pkd1 and Pkd2 mouse mutants, and decreasing BUN and cAMP levels of jck 
mutants. Additionally, immunohistochemistry for GLI1 revealed its localization to the nucleus of 
renal cyst-lining epithelial cells as well as of cells within the interstitium, indicating autocrine and 
paracrine Hh signaling, similar to human ADPKD tissues (Chapter 2). Finally, GLI1 levels/Hh 




Chapter 2, connecting increased Hh signaling with disease progression and further supporting that 
downregulation of Hh signaling may delay disease progression.  
Together, our studies suggest enhanced Hh activity contributes to renal cyst progression in 
ADPKD, and thus, Hh inhibition may be a potential novel therapeutic strategy. Since several Hh 
inhibitors are FDA-approved in the United States, these can potentially be repurposed for ADPKD.  
 
 5.1.2 A potential role for STAT3 signaling in initiating renal cystic disease in a ciliary mouse 
model 
In Chapters 2 and 3, we are the first to suggest Hh signaling as a mechanism that plays a 
role in ADPKD progression. However, what signaling pathways initiate renal cystogenesis 
continues to be another outstanding question in the PKD field.  To uncover novel molecules that 
may initiate renal cystogenesis, we performed RNA sequencing in pre-cystic and cystic kidneys 
of Thm1 cko mice, reasoning that genes misexpressed before cysts are formed and during disease 
progression may influence renal cyst initiation.  With this reasoning, our data suggest that 
increased expression of Stat3, Fos, Jun, Endothelin1, Vcam1, Ccl2, Complement C3, Egr2 and 
Adcy7 may initiate renal cystic disease. In my validation of these molecules at the protein level, I 
have shown that STAT3 signaling activity is significantly increased in pre-cystic and cystic 
kidneys. STAT3 signaling has been reported to contribute to PKD progression [205, 206], but we 
are the first to suggest a role for STAT3 signaling in renal cyst initiation. To investigate the 
molecular mechanisms by which Thm1 deficiency causes upregulation of STAT3 signaling, I 
treated control and THM1 kd 293T human renal cells with IL6, a cytokine that activates STAT3 




activation that is preceded by robust ERK activation.  These data indicate that THM1 regulates 
ERK and STAT3 signaling. 
The other nine molecules identified by RNA seq to be upregulated in pre-cystic and cystic 
Thm1 cko kidneys may also contribute to renal cyst initiation, either independently or by 
converging on STAT3 signaling. Several reports show a very influential role of the immune system 
on renal cystogenesis in ADPKD, including via STAT3 signaling [183, 200-202]. Our RNA Seq 
data revealed several immune-related genes, including Ccl2/Mcp1, to be upregulated in pre-cystic 
kidneys. Recently, polycystin-1 was reported to interact with ciliary-localized LKB1 to decrease 
CCL2/MCP1 and consequently regulate inflammation through primary cilia [131].   Pkd1,Ccl2 
double knock-out mice showed reduced renal cystogenesis, indicating the immune reaction 
triggered by CCL2 may link primary cilia to renal cystic disease [131]. These data suggest that the 
increased expression of Ccl2 in our mouse model may also contribute to renal cyst formation.  
Interestingly, Ccl2 has been shown to be a target of STAT3 signaling in prostate cancer [207]. A 
similar mechanism may also occur in the kidney connecting STAT3 signaling to CCL2 and renal 
cyst initiation. 
In summary, our study has identified molecules and pathways, particularly STAT3 
signaling, that are misexpressed before cysts are formed. We propose that these molecules play a 
role in renal cyst initiation.  
 
5.2 Future Directions 
5.2.1 Expanding the knowledge of Hh signaling in ADPKD progression 




In Chapter 2, my findings suggest increased Hh signaling plays a role in human ADPKD 
progression. To expand on these findings, we can correlate Hh signaling with age and disease 
severity of ADPKD kidney samples, and anticipate that upregulation of Hh signaling in the kidney 
will increase in patients with worsening prognosis. In addition to a role for Hh signaling in renal 
epithelial cells [138, 149], increased Hh signaling in fibroblasts has previously shown to contribute 
to fibrosis [147] and may also stimulate fibrosis in ADPKD. Future experiments can examine the 
role of Hh signaling in fibrosis, beginning with co-immunostaining interstitial cells, such as 
fibroblasts, with GLI1. Finally, since cilia length may associate with disease severity in mice [29, 
55], we can quantify cilia length in ADPKD renal tissue using immunostaining and ImageJ for 
quantification to examine if ADPKD renal tissue has longer primary cilia than NHK renal tissue.  
I did not observe cilia length differences between NHK and ADPKD primary renal epithelial cells, 
however, extraction and culture of cells could have influenced cilia length. Similarly, increased 
Hh signaling was not observed in ADPKD primary renal epithelial cells, in contrast to the 
immunohistochemistry findings on ADPKD renal sections.     
 
5.2.1.2 Examine interconnection between Hh and Ca2+ signaling 
Additionally, in Chapter 2, Hh inhibitors reduced basal and cAMP-mediated cell 
proliferation and cyst formation of ADPKD cells in vitro. The combination of decreased 
intracellular Ca2+ levels and aberrant cAMP activity leads to increased cell proliferation of 
ADPKD cells, which in turn, facilitates cyst growth [49, 52]. Importantly, increasing intracellular 
calcium reverts the abnormal activity of cAMP [51]. To determine if Hh inhibitors reduce ADPKD 
cell proliferation by increasing intracellular Ca2+, we can treat cells with DMSO or Hh inhibitors 




examine Ca2+ levels in the cytosol.  We can also treat cells with ionomycin, a calcium ionophore 
that increases Ca2+ in the cytosol and in cilia and compare the effects of ionomycin and of Hh 
inhibitors on cAMP-induced proliferation [40]. To further support that Hh inhibitors increase 
intracellular Ca2+, we may treat ADPKD cells with high concentrations of ionomycin, which 
should induce a substantial increase in intracellular Ca2+, and compare cell proliferation to cells 
treated with low concentrations of ionomycin combined with low concentrations of Hh inhibitors. 
If Hh inhibitors are modulating calcium, combinatory treatment would result in similar 
proliferation behavior to higher ionomycin alone. To examine cAMP, we can use the cADDis 
cAMP Sensor BacMam kits to determine if Hh inhibitors affect ciliary or cytosolic cAMP levels.  
Additionally, we can determine which Ca2+ pool - ciliary or cytosolic - drives proliferation 
of ADPKD cells.  We can treat ADPKD cells with cAMP in combination with various Ca2+ 
modulators, such as fenoldopam, ionomycin and thrombin [86]. Fenoldopam increases ciliary Ca2+ 
only. Ionomycin elevates ciliary and cytosolic Ca2+ and thrombin increases Ca2+ in the cytosol 
only [86]. If fenoldopam reduces cell proliferation, this would suggest ciliary Ca2+ reverses cAMP-
stimulated proliferation of ADPKD cells. If thrombin decreases cell proliferation, this would 
indicate cytosolic Ca2+ is more important to regulate cAMP-induced cell proliferation. Finally, if 
ionomycin is the only treatment that counteracts the increased cell proliferation, this would suggest 
that both ciliary and cytosolic Ca2+ modulate cell proliferation of ADPKD cells.  
Another gap in knowledge we can address is whether the converse regulation exists.  Does 
Ca2+ regulate Hh signaling? And is this regulation compromised in ADPKD? To determine this, 
we can stimulate Hh signaling by treating ADPKD cells with SAG, alone, and in combination with 
Ca2+ channel blockers, gadolinium or verapamil.  Gadolinium prevents cytosolic Ca2+ from being 




If activation of the pathway depends on ciliary Ca2+, treatment with verapamil will inhibit Hh 
signaling. However, if both treatments inhibit Hh activity, then this would suggest the cytosolic 
Ca2+ pool is the most important for activation of the pathway.  
 
5.2.1.3 Examine epigenetics as a regulator of Hh signaling 
Alternatively, epigenetics may cause upregulation of Hh signaling in ADPKD tissues.  In 
cultured medulloblastoma and basal cell carcinoma mouse-tumor-derived cells, inhibition of Brd4, 
an epigenetic regulator, reduced Gli1 expression [178].  In addition, treatment of a 
medulloblastoma mouse model with I-BET151, a Brd4 inhibitor, reduced Gli1 expression and 
tumor growth [167]. Further, I-BET151 treatment attenuated PKD progression in a Pkd1 cko 
mouse [166]. To examine whether epigenetics also targets the Hh pathway in ADPKD, we can 
treat ADPKD primary cells with SAG together with I-BET151 or with I-BET51 alone. If 
epigenetics is regulating the Hh pathway, then resulting Hh gene expression and cell proliferation 
should be comparable to the effects of the Hh inhibitors reported in Chapter 2.  
 
5.2.1.4 Connecting Hh and ERK signaling 
 Finally, Hh and ERK pathways have been reported to synergize in some cancers [168-
170]. We can examine if these pathways also synergize in ADPKD by comparing the effects of 
treating primary cells with Hh and ERK inhibitors, individually, and in combination. If these 
pathways synergize in ADPKD, I expect that treating cells with both Hh and ERK inhibitors will 




Combined these experiments will further connect primary cilia and Hh signaling to 
ADPKD biology and may provide further support of Hh signaling as a potential therapeutic target 
for ADPKD. 
 
5.2.2 Expanding investigation of Hedgehog signaling in disease progression in ADPKD mouse 
models 
In Chapter 3, we show promising data suggesting that genetic downregulation of Hh 
signaling in ADPKD mouse models, jck and Pkd1, ameliorates renal cystic disease. Future 
directions will include obtaining statistical significance for reduction in %KW/BW, cAMP, BUN 
and cystic index. Additionally, we will validate downregulation of Hh signaling by examining Gli1 
expression either through qPCR or Western Blot.  Cell proliferation and fibrosis can also be 
examined. We can also address if ciliary length was altered by downregulation of Hh signaling as 
jck and Pkd1 mutants were reported to have increased ciliary length that may contribute to disease 
[29, 55, 57]. Lastly, because cooperation between Hh and ERK signaling has previously been 
reported in cancer studies [168-170], we can determine if Hh inhibitors also modulated ERK 
signaling, which would indicate a connection between these two pathways in PKD. The results of 
the suggested experiments will further support Hh inhibitors as potential components for therapy 
against ADPKD. 
  
5.2.3 Expanding knowledge of ciliary mechanisms that contribute to renal cyst initiation  
5.2.3.1 Examine subcellular localization of STAT3 signaling components  
Chapter 4 suggests elevated STAT3 signaling contributes to renal cyst initiation in Thm1 




cilia. Subcellular localization of STAT3, P-STAT3, and JAK2, a kinase that phosphorylates and 
activates STAT3 [204], can be examined in THM1 kd and control 293T cells using 
immunofluorescence.   If STAT3 signaling components localize to primary cilia, we can examine 
whether ciliary-localized PC1 may be activating STAT3 signaling in this in vitro system. A 
proximity ligation assay can be performed to determine whether THM1, STAT3, JAK2 and/or 
PC1 form a complex in cilia. Additionally, since STAT6 is a cilia-localized protein that can be 
activated by PC1 [211] and is upregulated in cystic kidneys of Thm1 cko mice, we can perform 
similar experiments for STAT6 as well.  
Since we show that THM1 kd 293T cells have increased activation of ERK and STAT3 
signaling when treated with IL-6, we can determine if the regulation of these pathways is 
dependent on primary cilia, by treating cells with chloral hydrate, which removes primary cilia 
from cells [85, 218]. If regulation of ERK and STAT3 signaling relies on primary cilia, I would 
expect reduced activation of these pathways by IL-6, in cells treated with chloral hydrate. 
 
5.2.3.2 Connect STAT3, ERK and cAMP signaling in THM1 kd cells 
 To broaden the signaling network, we can then examine the connection between cAMP, 
STAT3 and ERK signaling.  cAMP is increased in the kidneys of Thm1 cko mice, and treating 
THM1 kd 293T cells with cAMP might increase ERK and STAT3 activation and cell proliferation, 
recapitulating the in vivo events. We can also combine treatment of cAMP with IL6 to determine 
if this causes even greater cell proliferation than either treatment alone, and conversely, combine 
treatment of cAMP with a STAT3 inhibitor, such as Stattic, to determine if this decreases cAMP-
induced cell proliferation, suggesting cAMP may act in part via STAT3 signaling. To address 




different combinations of cAMP, a specific MEK inhibitor, like PD098059 [209], and a STAT3 
inhibitor, such as Stattic, and examine cell proliferation. Since ERK signaling is upregulated in 
cystic kidneys of Thm1 cko mice and in IL6-treated THM1 kd 293T cells (Chapter 4), we expect 
ERK inhibition to decrease cell proliferation. If ERK signaling has a more influential role than 
STAT3 signaling in inducing proliferation of THM1-deficient cells, ERK inhibitor may show a 
greater decrease in cell proliferation, compared to Stattic-treated cells. If ERK and STAT3 
signaling are both essential in inducing cell proliferation, treating THM1 kd cells with both ERK 
and STAT3 inhibitors may provide a greater reduction in cell proliferation, compared to treatment 
with a single inhibitor.  
 To demonstrate that increased STAT3 signaling is causative of Thm1 cko renal cystic 
disease, we will continue to pursue treatments with C188-9, which showed the most promising 
reduction of STAT3 signaling in vivo.  We will increase the dose of C188-9 and expand mouse 
numbers. We will then determine %KW/BW ratios, cystic index, BUN, and examine fibrosis and 
cell proliferation in tissue sections. Alternatively, we can genetically delete Stat3, either 
specifically in kidneys or globally in a time-dependent manner, using a Cre-ROSA26ERT allele, in 
our mouse model [208]. 
 Finally, to determine if other molecules that are upregulated in pre-cystic kidneys of Thm1 
cko mice contribute to renal cyst initiation, we can treat 293T cells with these molecules and 
examine STAT3 and ERK activation and cell proliferation.  Interestingly, endothelin-1 (ET-1) 
induces secretion of IL-6 in osteoblast-like cells [212], and may similarly contribute to 
upregulation of STAT3 pathway in Thm1-deficient kidneys. Another molecule we are interested 
in is CCL2.   CCL2 was recently reported to contribute to early renal cystic disease via a ciliary-




prostate cancer [207]. We can examine Ccl2 expression in kidneys of our mutant mice, as well as 
in our THM1 kd 293T cells, to validate whether Thm1 deficiency increases Ccl2, as suggested by 
our RNA seq data, and may in turn contribute to the renal cystic phenotype in our model. 
 
5.2.3.3 Examine PC1 function in THM1-deficient cilia 
Another way to further our knowledge of the ciliary mechanisms that contribute to renal 
cyst initiation in Thm1 cko mice is to determine whether PC1 functions properly in Thm1-deficient 
cilia. PC1 activates the Calcineurin/NFAT (Nuclear Factor of Activated T cells) signaling pathway 
by sustaining increased intracellular calcium levels [219]. To determine whether the THM1 cilia 
defect affects PC1 function, we can use calcineurin/NFAT signaling pathway as a read-out. We 
can transfect THM1 kd and control 293T cells with PC1 C-tail or a control construct and examine 
NFAT signaling before and after caffeine treatment, which stimulates an increase in intracellular 
calcium [219]. If primary cilia dysfunction affects PC1 activity, the control transfected 293T cells 
will sustain increased calcium levels, while the THM1 kd cells will not.  We can also treat cells 
with CSA, a calcineurin inhibitor, as a negative control [219]. We expect that THM1 kd cells will 
be unable to sustain calcium levels, and therefore will not show calcineurin-dependent NFAT 
activation, reflective of defective PC1 function.  
 The PC1 C-tail can also activate STAT3 signaling [206], and thus, may activate STAT3 
signaling in THM1 kd 293T cells.  To determine this, we can examine whether levels of PC1 C-
tail are increased in Thm1 cko pre-cystic kidneys [211]. We can also transfect THM1 kd and control 
293T cells with PC1 C-tail alone and in combination with IL-6 to activate STAT3 signaling, or 
with Stattic to inhibit STAT3 signaling, and examine STAT3 activation using Western blot. The 




transfected with PC1 C-tail, indicating PC1 tail has ability to activate STAT3 signaling. Treatment 
with Stattic will reduce STAT3 activity. Combined, these experiments will help determine if PC1 
activity is dysregulated by Thm1 deficiency.  
 
5.2.4 Examine effect of Thm1 deletion on a renal cystic disease background  
 Genetic removal of primary cilia rescued the cystic phenotype in Pkd1 and Pkd2 mouse 
models, suggesting an event or mechanism within primary cilia is essential to renal cystogenesis 
in PKD [58]. Deletion of Thm1 does not ablate primary cilia, but shortens primary cilia and affects 
protein trafficking within cilia.  Thm1 deletion can also have opposing effects on signaling 
pathways than deletion of genes essential for cilia formation [25].  Furthermore, a role for IFT-B 
has been shown in ADPKD mouse models [58], but a role for IFT-A in ADPKD mouse models 
has not been reported. This prompted us to investigate the effects of deletion of Thm1, an IFT-A 
gene, on renal cystic disease in Pkd1 cko mice. We conditionally deleted both genes at 5 weeks of 
age, resulting in a slowly progressing model of renal cystic disease. We dissected animals at 6 
months of age (Figure 5.2.4.1A). At 4 months of age (data not shown), renal cysts in Pkd1 cko 
mice are beginning to appear. At 6-months of age, Pkd1 cko mice show moderate disease 
progression, and double-mutants show reduced %KW/BW and BUN level, indicating deletion of 
Thm1 reduced renal cystogenic potential and improved renal function (Figure 5.2.4.1B,C). The 
cysts in double-mutant kidneys derive from collecting ducts, and cell proliferation is reduced in 
Pkd1,Thm1 kidneys, compared to single mutants (Figure 5.2.4.2 and Figure 5.2.4.3).  
 Additionally, we examined fibrosis using immunofluorescence for smooth-muscle actin 
(SMA) antibody on kidney sections. However, not a lot of fibrosis was detected by this method in 




deleting Thm1 together with Pkd1 is reduction of renal cystogenesis. We performed Western Blot 
analysis on whole kidney extracts and observed that STAT3 and ERK signaling activity correlates 
with disease severity, with Pkd1,Thm1 dko kidneys showing less ERK and STAT3 activation than 
Pkd1 cko kidneys (Figure 5.2.4.5). Since increased ciliary length has been reported in the 
Pkd1RC/RC mouse model [29, 55], we also examined cilia phenotype in collecting ducts by 
immunostaining kidney sections using antibodies against acetylated -tubulin, a ciliary marker, 
together with DBA lectin staining. Pkd1 cko kidneys have strikingly longer primary cilia than 
wild-type kidneys (Figure 5.2.4.6), while Pkd1,Thm1 dko kidneys have shorter primary cilia than 
Pkd1 cko kidneys, similar to wild-type (Figure 5.2.4.6). Combined, these data are the first to 
demonstrate that IFT-A is essential to renal cystogenesis and dysregulated ciliogenesis in Pkd1 
cko mice.  Increased cilia length has been reported in other ADPKD mouse models and may alter 
signaling pathways leading to renal cystogenesis. Further ciliary analyses will be performed to 
determine if the Pkd1,Thm1 dko cilia have a similar phenotype to Thm1 cko cilia or have a rescued 
cilia phenotype. 
 Future directions will address the mechanisms underlying the striking attenuation of renal 
cystic disease in Pkd1,Thm1 cko mice. For instance, we can perform single-cell RNA Sequencing 
to compare collecting duct-derived cells from control, Pkd1 cko and Pkd1,Thm1 dko mice and 
suggest novel molecules that we can investigate as therapeutic targets.  In addition to signaling 
molecules, we can also look for genes that are known to regulate ciliogenesis as misregulation of 
these genes could cause differences in cilia length between single and double-mutant renal cells. 
Additionally, we can generate primary renal cells from the single and double knock-out mutants 
or knock-down the genes in 293T renal cells and analyze localization and expression of ciliary 




disassembly and/or ciliary entry of membrane proteins, which could reveal additional mechanisms 
that lead to enhanced or rescued renal cystogenesis.  
Additionally, we can examine the ciliary-dependent LKB1-Ccl2 pathway in Thm1 cko and 
Pkd1, Thm1 dko kidneys, as this pathway has been shown to be misregulated in Pkd1 cko mice 
and rescued by deletion of cilia [131].  Since THM1 is an IFT protein, THM1 may play a role in 
the transport of molecules that regulate Ccl2, such as the ciliary LKB1- NEK7-ANKS3-NPHP1 
complex. Future experiments will include immunofluorescence and proximity ligation assays 
using THM1, LKB1 and ANKS3 antibodies to determine if THM1 interacts with any of these 
proteins within cilia of 293T human renal cells. If THM1 interacts with these proteins and this 
interaction is compromised in THM1 deficient cells, this would suggest that THM1 is important in 
CCL2 regulation in the presence of intact cilia.  Our RNA seq data revealed increased Ccl2 in pre-
cystic kidneys of Thm1 cko mice, generated by deleting Thm1 cko at P0.  Of note, however, these 
Pkd1,Thm1 dko mice were generated by deleting the genes at 5 weeks of age.  Thus, these 
experiments may reveal whether the effect of THM1 on LKB1-Ccl2 signaling differs in rapidly-






















Figure 5.2.4.1: Deletion of Thm1 ameliorates renal cystic disease in Pkd1 cko mice. 
A) Whole kidney images show Pkd1,Thm1 dko have smaller kidneys, compared to Pkd1 cko mice. 
B) Pkd1,Thm1 dko mice have lower %KW/BW and BUN levels. Statistical significance was 









Figure 5.2.4.2: Pkd1,Thm1 dko kidneys show cysts that derive from collecting duct. 















Figure 5.2.4.3: Pkd1,Thm1 dko kidneys show less cell proliferation than Pkd1 cko kidneys. 












Figure 5.2.4.4: Pkd1,Thm1 dko and Pkd1 cko kidneys do not show much fibrosis. 









Figure 5.2.4.5: STAT3 and ERK signaling activity correlates with disease severity in 
Pkd1,Thm1 dko and Pkd1 cko kidneys. 








Figure 5.2.4.6: Deletion of Thm1 rescues lengthened cilia in Pkd1 cko mice. 
Immunofluorescence using acetylated -tubulin as a ciliary marker and DBA as a collecting duct 
















5.3 Significance of these studies 
 ADPKD is a genetic disease that affects 1:500 people worldwide, leading to compromised 
renal function [35].  With limited therapy and no cure, ADPKD results in over a billion dollars 
spent every year in health care around the world [132]. Primary cilia appear to play a central role 
in the pathogenesis of ADPKD [35], yet the mechanisms by which primary cilia contribute to renal 
cystogenesis are not well-established. We proposed to uncover the ciliary-mediated pathway(s) 
that are dysregulated and contribute to cyst growth. We used in vitro and in vivo systems and are 
the first to suggest cilia-mediated Hh signaling plays a role in ADPKD progression, and increased 
STAT3 signaling may play a role in renal cyst initiation. There are FDA-approved Hh and STAT3 
inhibitors, which can be potentially repurposed and investigated as components of combinatorial 














Figure 5.3: Summary of findings. 
Our research aims to understand the mechanisms connecting primary cilia to renal cystogenesis in 
PKD. Our findings suggest STAT3 signaling may initiate renal cystogenesis in a ciliary mouse 
model, and that Hh signaling plays a role in renal cystic disease progression in human ADPKD 
and ADPKD mouse models. The link between primary cilia and STAT3 signaling, and STAT3 
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